Mkb 10 benign lung formation. Neoplasms (C00-D48)

This class contains the following broad groups of neoplasms: C00-C75 Malignant neoplasms of specified localizations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues C00-C14 Lips, oral cavity and pharynx C15-C26 Digestive organs C30-C39 Respiratory organs and chest С40-С41 Bones and articular cartilage С43-С44 Skin С45-С49 Mesothelial and soft tissues С50 Breast С51-С58 Female genital organs С60-С63 Male genital organs С64-С68 Urinary tract С69-С72 Eyes, brain and other parts of the central nervous system С73-С75 Thyroid gland and other endocrine glands С76-С80 Malignant neoplasms of inaccurately marked, secondary and unspecified localizations С81-С96 Malignant neoplasms of lymphoid, hematopoietic and related tissues, which are designated as primary or presumably primary С97 Malignant neoplasms independent (primary b) multiple localizations D00-D09 In situ neoplasms D10-D36 Benign neoplasms D37-D48 Neoplasms of uncertain or unknown nature [see note on p. 242] NOTES 1. Malignant neoplasms, primary, ill-defined and unspecified sites Categories C76-C80 include malignant neoplasms with an imprecisely designated primary site or those defined as "disseminated", "diffuse" or "widespread" without an indication of the primary site ... In both cases, the primary site is considered unknown. 2. Functional activity Class II is classified as neoplasm, regardless of the presence or absence of functional activity. If it is necessary to clarify the functional activity associated with a particular neoplasm, an additional code from class IV can be used. For example, catecholamine-producing malignant pheochromocytoma of the adrenal glands is coded under the rubric C74 with the additional code E27.5; basophilic adenoma of the pituitary gland with Itsenko-Cushing's syndrome is coded under the heading D35.2 with the additional code E24.0. 3. Morphology There are a number of large morphological (histological) groups of malignant neoplasms: carcinomas, including squamous cell and adenocarcinomas; sarcomas; other soft tissue tumors including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other specified and localization-specific types; unspecified cancers. The term "cancer" is generic and can be used for any of the above groups, although it is rarely used to refer to malignant neoplasms of lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used synonymously with the term "cancer". In class II, neoplasms are classified mainly by localization within broad groupings, based on the nature of the course. In exceptional cases, the morphology is indicated in the names of headings and subheadings. For those wishing to identify the histological type of neoplasm on p. 577-599 (vol. 1, part 2) provides a general list of individual morphological codes. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classified system that provides independent coding of neoplasms in terms of topography and morphology. Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (primary malignant, secondary malignant, ie metastatic, in situ, benign, undefined), and the sixth character defines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias. 4. Use of subheadings in class II Attention is drawn to the special use in this class of subheadings with sign 8 (see note 5). Where it is necessary to highlight a subheading for the group "others", subheading is usually used. 7. 5. Malignant neoplasms that go beyond one localization and the use of a subheading with a fourth character.8 (lesion that goes beyond one or more of the specified localizations) Columns C00-C75 classify primary malignant neoplasms according to their place of origin. Many three-digit headings are further subdivided into sub-headings according to the different parts of the bodies concerned. A neoplasm that covers two or more adjacent localizations within a three-digit heading and the place of origin of which cannot be determined should be classified under a sub-heading with a fourth character.8 (a lesion that goes beyond one or more of the above localizations), if such the combination is not specifically indexed in other headings. For example, carcinoma of the esophagus and stomach is coded C16.0 (cardia), while carcinoma of the tip and lower surface of the tongue should be coded under the subheading C02. 8.On the other hand, carcinoma of the tip of the tongue involving its lower surface should be coded in the subheading C02.1, since the place of occurrence (in this case, the tip of the tongue) is known

The clinical manifestations of benign lung tumors depend on the localization of the neoplasm, its size, direction of growth, hormonal activity, the degree of bronchial obstruction, caused by complications.
Benign (especially peripheral) lung tumors may not give any symptoms for a long time. In the development of benign lung tumors, there are:
asymptomatic (or preclinical) stage.
the stage of the initial clinical symptoms.
the stage of severe clinical symptoms due to complications (bleeding, atelectasis, pneumosclerosis, abscess pneumonia, malignancy and metastasis).
With peripheral localization in the asymptomatic stage, benign lung tumors do not manifest themselves. At the stage of initial and severe clinical symptoms, the picture depends on the size of the tumor, the depth of its location in the lung tissue, the relationship to the adjacent bronchi, vessels, nerves, and organs. Large lung tumors can reach the diaphragm or chest wall, causing chest or heart pain and shortness of breath. In the case of vascular erosion by a tumor, hemoptysis and pulmonary hemorrhage are observed. Compression of large bronchi by a tumor causes a violation of bronchial patency.
Clinical manifestations of benign lung tumors of central localization are determined by the severity of violations of bronchial patency, in which grade III is distinguished:
I degree - partial bronchial stenosis;
II degree - valvular or ventral bronchial stenosis;
III degree - bronchial occlusion.
In accordance with each degree of impairment of bronchial patency, the clinical periods of the disease differ. In the 1st clinical period, corresponding to partial bronchial stenosis, the lumen of the bronchus is slightly narrowed, therefore, its course is often asymptomatic. Sometimes there is a cough, with a small amount of sputum, less often with an admixture of blood. The general state of health does not suffer. Radiographically, a lung tumor in this period is not detected, but can be detected by bronchography, bronchoscopy, linear or computed tomography.
In the 2nd clinical period, valvular or ventral stenosis of the bronchus develops, associated with obturation by a tumor of most of the bronchial lumen. In valve stenosis, the lumen of the bronchus partially opens on inspiration and closes on expiration. In the part of the lung, ventilated by a narrowed bronchus, expiratory emphysema develops. Complete closure of the bronchus may occur due to edema, accumulation of blood and sputum. An inflammatory reaction develops in the lung tissue located at the periphery of the tumor: the patient's body temperature rises, cough with phlegm, shortness of breath, sometimes hemoptysis, chest pains, fatigue and weakness appear. Clinical manifestations of central lung tumors in the 2nd period are intermittent. Anti-inflammatory therapy relieves swelling and inflammation, leads to the restoration of pulmonary ventilation and the disappearance of symptoms for a certain period.
The course of the 3rd clinical period is associated with the phenomena of complete occlusion of the bronchus by a tumor, suppuration of the atelectasis zone, irreversible changes in the area of \u200b\u200blung tissue and its death. The severity of symptoms is determined by the caliber of the bronchus obturated by the tumor and the volume of the affected area of \u200b\u200bthe lung tissue. There is a persistent rise in temperature, severe chest pain, weakness, shortness of breath (sometimes attacks of suffocation), feeling unwell, cough with purulent sputum and blood, sometimes pulmonary bleeding. X-ray picture of partial or complete atelectasis of a segment, lobe or the whole lung, inflammatory and destructive changes. Linear tomography reveals a characteristic picture, the so-called "bronchial stump" - a break in the bronchial pattern below the obstruction zone.
The speed and severity of violations of bronchial patency depends on the nature and intensity of growth of the lung tumor. With peribronchial growth of benign lung tumors, clinical manifestations are less pronounced, complete occlusion of the bronchus rarely develops.

Diagnosis with the C00-D48 code includes 4 clarifying diagnoses (ICD-10 headings):

1. C00-C97 - Malignant neoplasms
   Contains 15 blocks of diagnoses.
2. D00-D09 - In situ neoplasms
   Contains 9 blocks of diagnoses.
   Included: Bowen's disease erythroplasia morphological codes with the code of the nature of the neoplasm / 2 erythroplasia Keir.
3. D10-D36 - Benign neoplasms
   Contains 27 blocks of diagnoses.
   Included: morphological codes with the code of the nature of the neoplasm / 0.
4. D37-D48 - Neoplasms of uncertain or unknown nature
   Contains 12 blocks of diagnoses.

Explanation of the disease with code C00-D48 in the MBK-10 handbook:

Notes

1. Malignant neoplasms, primary, inaccurately indicated and unspecified localizations
   Headings C76-C80 include malignant neoplasms with an imprecisely designated primary site, or those defined as "disseminated", "disseminated", or "widespread" with no indication of the primary site. In both cases, the primary site is considered unknown.
2. Functional activity
   Class II includes neoplasms regardless of the presence or absence of functional activity. If it is necessary to clarify the functional activity associated with a particular neoplasm, an additional code from class IV can be used. For example, catecholamine-producing malignant pheochromocytoma of the adrenal glands is coded under the heading C74 with the additional code E27.5; basophilic adenoma of the pituitary gland with Itsenko-Cushing's syndrome is coded under the heading D35.2 with the additional code E24.0.
3. Morphology
   There are a number of large morphological (histological) groups of malignant neoplasms: carcinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other specified and localization-specific types; unspecified cancers. The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used synonymously with the term "cancer".
   In class II, neoplasms are classified mainly by localization within broad groupings, based on the nature of the course. In exceptional cases, morphology is indicated in the names of headings and subheadings.
   For those wishing to identify the histological type of neoplasm on p. 577-599 (vol. 1, part 2) provides a general list of individual morphological codes. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classified system that provides independent coding of neoplasms in topography and morphology.
   Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indeterminate), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.
4. Use of subheadings in class II
   Attention is drawn to the special use in this class of subheadings with sign 8 (see note 5). Where it is necessary to highlight a subheading for the group "others", the subheading is usually used. 7.
5. Malignant neoplasms that go beyond one localization, and the use of a subheading with a fourth character. 8 (a lesion that goes beyond one or more of the specified localizations)
   Headings C00-C75 classify primary malignant neoplasms according to their place of origin. Many three-digit headings are further subdivided into sub-headings according to the different parts of the bodies concerned. A neoplasm that covers two or more adjacent localizations within a three-digit heading and the place of origin of which cannot be determined should be classified under a subheading with a fourth character.8 (a lesion that goes beyond one or more of the above localizations), unless such a combination is specifically indexed in others headings. For example, carcinoma of the esophagus and stomach is coded C16.0 (cardia), while carcinoma of the tip and lower surface of the tongue should be coded C02.8. On the other hand, carcinoma of the tip of the tongue involving the lower surface of the tongue should be coded in the subheading C02.1, since the place of occurrence (in this case, the tip of the tongue) is known.
   The concept of "a lesion that goes beyond one or more of the above localizations" means that the involved areas are adjacent (one continues the other). The numbering sequence of the subheadings often (but not always) corresponds to the anatomical neighborhood of sites (eg, bladder C67.-), and the coder may have to consult anatomical reference books to determine topographic relationships.
   Sometimes the neoplasm goes beyond the localizations indicated by three-digit headings within one organ system. The following subheadings are intended to encode such cases:
   C02.8 Language affection beyond one or more of the above localizations
   C08.8 Lesion of the large salivary glands, beyond one or more of the above localizations
   C14.8 Lesion of lips, oral cavity and pharynx, going beyond one or more of the above localizations
   C21.8 Damage to the rectum, anus [anus] and anal canal, extending beyond one or more of the above localizations
   C24.8 Lesion of the biliary tract, beyond one or more of the above localizations
   C26.8 Lesion of the digestive system, going beyond one or more of the above localizations
   C39.8 Damage to the respiratory system and intrathoracic organs, going beyond one or more of the above localizations
   C41.8 Lesion of bones and articular cartilage, going beyond one or more of the above localizations
   C49.8 The defeat of the connective and soft tissues, beyond one or more of the above localizations
   C57.8 The defeat of the female genital organs, going beyond one or more of the above localizations
   C63.8 Lesion of the male genital organs, going beyond one or more of the above localizations
   C68.8 Disorder of urinary organs beyond one or more of the above localizations
   C72.8 Damage to the brain and other parts of the central nervous system, going beyond one or more of the above localizations
   An example is carcinoma of the stomach and small intestine, which should be coded in sub-heading C26.8 (lesions of the digestive system that go beyond one or more of the above sites).
6. Malignant neoplasms of ectopic tissue
   Ectopic tissue malignancies should be coded according to the location mentioned, for example, ectopic pancreatic malignancies should be coded as pancreatic, unspecified (C25.9).
7. Use of the Alphabetical Index when coding neoplasms
   When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for morphological description. The introductory pages in volume 3 include general instructions on using the Index. To ensure the correct use of the Class II headings and subheadings, special instructions and examples related to neoplasms must be taken into account.
8. Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)
   For some morphological types, class II provides a rather narrow topographic classification, or none at all. ICD-0 topographic codes are used for all neoplasms, essentially using the same three- and four-digit headings used in class II for malignant neoplasms (C00-C77, C80), thus providing greater localization accuracy for other neoplasms [secondary malignant ( metastatic), benign, in situ, uncertain or unknown].
   Therefore, institutions interested in determining the location and morphology of tumors (such as cancer registries, oncology hospitals, pathology departments, and other oncological services) should use ICD-0.

This class contains the following broad groups of neoplasms:

• С00-С75 Malignant neoplasms of specified localizations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues
  • C00-C14 Lips, oral cavity and pharynx
  • С15-С26 Digestive organs
  • С30-С39 Respiratory and chest organs
  • С40-С41 Bones and articular cartilage
  • C43-C44 Skin
  • С45-С49 Mesothelial and soft tissues
  • C50 Breast
  • С51-С58 Female genital organs
  • C60-C63 Male genital organs
  • С64-С68 Urinary tract
  • С69-С72 Eyes, brain and other parts of the central nervous system
  • С73-С75 Thyroid gland and other endocrine glands
• С76-С80 Malignant neoplasms of ill-defined, secondary and unspecified localizations
• С81-С96 Malignant neoplasms of lymphoid, hematopoietic and related tissues, which are designated as primary or presumably primary
• C97 Malignant neoplasms of independent (primary) multiple localizations
• D00-D09 In situ neoplasms
• D10-D36 Benign neoplasms
• D37-D48 Neoplasms of uncertain or unknown nature [see note on p. 242]

Print

Class II. Neoplasms (C00-D48)

This class contains the following broad groups of neoplasms:

С00-С75 Malignant neoplasms of specified localizations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues
C00-C14 Lips, oral cavity and pharynx
С15-С26 Digestive organs
С30-С39 Respiratory and chest organs
С40-С41 Bones and articular cartilage
C43-C44 Skin
С45-С49 Mesothelial and soft tissues
C50 Breast
С51-С58 Female genital organs
C60-C63 Male genital organs
С64-С68 Urinary tract
С69-С72 Eyes, brain and other parts of the central nervous system
С73-С75 Thyroid gland and other endocrine glands
С76-С80 Malignant neoplasms of ill-defined, secondary and unspecified localizations
С81-С96 Malignant neoplasms of lymphoid, hematopoietic and related tissues, which are designated as primary or presumably primary
C97 Malignant neoplasms of independent (primary) multiple localizations
D00-D09 In situ neoplasms
D10-D36 Benign neoplasms
D37-D48 Neoplasms of uncertain or unknown nature

NOTES
1. Malignant neoplasms, primary, inaccurately designated and unspecified localizations
Headings C76-C80 include malignant neoplasms with an inaccurately designated primary site or those defined as "disseminated", "disseminated" or "widespread" with no indication of the primary site. In both cases, the primary site is considered unknown.

2. Functional activity
Class II includes neoplasms regardless of the presence or absence of functional activity. If it is necessary to clarify the functional activity associated with a particular neoplasm, an additional code from class IV can be used. For example, catecholamine-producing malignant pheochromocytoma of the adrenal glands is coded under the heading C74 with the additional code E27.5; basophilic adenoma of the pituitary gland with Itsenko-Cushing's syndrome is coded under the heading D35.2 with the additional code E24.0.

3. Morphology
There are a number of large morphological (histological) groups of malignant neoplasms: carcinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other specified and localization-specific types; unspecified cancers.

The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used synonymously with the term "cancer".

In class II, neoplasms are classified mainly by localization within broad groupings, based on the nature of the course. In exceptional cases, morphology is indicated in the names of headings and subheadings. For those wishing to identify the histological type of neoplasm on p. 577-599 (vol. 1, part 2) provides a general list of individual morphological codes. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classified system that provides independent coding of neoplasms in topography and morphology. Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indeterminate), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.

4. Use of subheadings in class II
Attention should be paid to the special use of subheadings with the sign 8 in this class. Where it is necessary to highlight a sub-heading for the group "others", the sub-heading is usually used. 7.

5. Malignant neoplasms that go beyond one localization, and the use of a subheading with a fourth character.8 (a lesion that goes beyond one or more of the specified localizations). Headings C00-C75 classify primary malignant neoplasms according to their place of origin. Many three-digit
The headings are further subdivided into sub-headings according to the different parts of the bodies concerned. A neoplasm that covers two or more adjacent localizations within a three-digit heading and the place of origin of which cannot be determined should be classified under a subheading with a fourth character.8 (a lesion that goes beyond one or more of the above localizations), unless such a combination is specifically indexed in others headings. For example, carcinoma of the esophagus and stomach is coded C16.0 (cardia), while carcinoma of the tip and lower surface of the tongue should be coded C02.8. On the other hand, carcinoma of the tip of the tongue involving the lower surface of the tongue should be coded in the subheading C02.1, since the place of occurrence (in this case, the tip of the tongue) is known. The concept of "a lesion that goes beyond one or more of the above localizations" means that the involved areas are adjacent (one continues the other). The numbering sequence of the subheadings often (but not always) corresponds to the anatomical neighborhood of the localization (eg, bladder C67.-), and the encoder may be forced to refer to the anatomical reference books to determine the topographic relationship. Sometimes the neoplasm goes beyond the localizations indicated
three-digit headings within one organ system. The following subheadings are intended to encode such cases:
C02.8 Defeat of the tongue, going beyond one or more of the above localizations
C08.8 The defeat of the large salivary glands, going beyond one or more of the above localizations
C14.8 Lesion of the lips, oral cavity and pharynx, going beyond one or more of the above localizations
C21.8 The defeat of the rectum, anus [anus] and anal canal, going beyond one or more of the above localizations
C24.8 Damage to the biliary tract, going beyond one or more of the above localizations
C26.8 Lesion of the digestive system, going beyond one or more of the above localizations
С39.8 Damage to the respiratory system and intrathoracic organs, going beyond one or more of the above localizations
C41.8 Damage to bones and articular cartilage, going beyond one or more of the above localizations
C49.8 The defeat of connective and soft tissues, beyond one or more of the above localizations
С57.8 The defeat of the female genital organs, going beyond one or more of the above localizations
C63.8 Lesion of the male genital organs, going beyond one or more of the above localizations
C68.8 Lesion of the urinary organs, beyond one or more of the above localizations
C72.8 Damage to the brain and other parts of the central nervous system, going beyond one or more of the above localizations

An example is carcinoma of the stomach and small intestine, which should be coded in subheading C26.8 (lesions of the digestive system that go beyond one or more of the above localizations).

6. Malignant neoplasms of ectopic tissue
Malignant neoplasms of ectopic tissue should be coded according to the localization mentioned, for example, ectopic malignant neoplasms of the pancreas should be coded as pancreatic, unspecified (C25.9).

7. Use of the Alphabetical Index when coding neoplasms
When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account, and first of all, it is necessary to refer to the Alphabetical Index for morphological description.
The introductory pages in volume 3 include general instructions on using the Index. In order to ensure the correct use of the headings and subheadings of class II, it is necessary to take into account the special instructions and examples related to the neoplasm.

8. Use of the second edition of the International Classification of Diseases in Oncology (ICD-O)
For some morphological types, class II provides a rather narrow topographic classification, or none at all. ICD-O topographic codes are used for all neoplasms using essentially the same three- and four-digit headings that are used in class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [secondary malignant ( metastatic
(i), benign, in situ, uncertain or unknown]. Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, oncological
hospitals, pathology departments and other services specializing in oncology), the ICD-O should be used.

Malignant neoplasms (C00-C97)

Malignant neoplasms of the lip, oral cavity and pharynx (C00-C14)

C00 Malignant neoplasm of the lip

Excludes: lip skin (C43.0, C44.0)

C00.0 The outer surface of the lip
Upper lip:
... NOS
... lip surface
... red border
C00.1 The outer surface of the lower lip
Lower lip:
... NOS
... lip surface
... red border
C00.2 Outer lip, unspecified. Red border NOS
C00.3 The inner surface of the upper lip
Upper lip:
... buccal surface
... bridles
... mucous membrane
... oral surface
C00.4 Inner surface of the lower lip
Lower lip:
... buccal surface
... bridles
... mucous membrane
... oral surface
C00.5Inner surface of lip, unspecified.
Lips without specifying upper or lower:
... buccal surface
... bridles
... mucous membrane
... oral surface
C00.6 Lip adhesions
C00.8 A lesion that goes beyond one or more of the above lip localizations
C00.9 Lips, unspecified

C01 Malignant neoplasms of the base of the tongue

The upper surface of the base of the tongue. Fixed part of the tongue NOS. Back third of the tongue

C02 Malignant neoplasm of other and unspecified parts of tongue

C02.0 Backs of the tongue. Front 2/3 of the back of the tongue.
Excludes: upper surface of base of tongue (C01)
C02.1 The lateral surface of the tongue. Tip of the tongue
C02.2 The lower surface of the tongue. Front 2/3 of the tongue lower surface. Tongue frenulum
C02.3 Anterior 2/3 of the tongue, part unspecified. Middle part of the tongue NOS. Movable part of the tongue NOS
C02.4 Lingual tonsil
Excludes: tonsils NOS (C09.9)
C02.8The defeat of the language, which goes beyond one or more of the above localizations.
Malignant neoplasm of the tongue, which at the place of origin cannot be attributed to any of the rub-
rick S01-S02.4
C02.9 Language of the unspecified part

C03 Malignant neoplasm of the gums

Includes: mucous membrane of the alveolar surface (crest) gingiva
Excludes: malignant odontogenic neoplasms (C41.0-C41.1)

C03.0 Gums of the upper jaw
C03.1 Gums of the lower jaw
C03.9 Gums, unspecified

C04 Malignant neoplasm of the floor of the mouth

C04.0 The front of the floor of the mouth. Anterior to the canine-premolar contact point
C04.1 Lateral part of the floor of the mouth
C04.8 The defeat of the floor of the oral cavity, which goes beyond one or more of the above localizations.
C04.9 Floor of mouth, unspecified

C05 Malignant neoplasm of palate

C05.0Solid sky
C05.1Soft palate
Excludes: nasopharyngeal surface of soft palate (C11.3)
C05.2 Uvula
C05.8 Lesions of the palate that go beyond one or more of the above localizations.
C05.9 Unspecified palate. Oral fornix

C06 Malignant neoplasm of other and unspecified parts of the mouth

C06.0 The mucous membrane of the cheek. Buccal mucosa NOS. Inner cheek
C06.1 Vestibules of the mouth. Buccal groove (upper, lower). Labial furrow (upper, lower)
C06.2 Retromolar area
C06.8 The defeat of the mouth, going beyond one or more of the above localizations.
C06.9 Mouth, unspecified. Small salivary gland, unspecified. Oral cavity NOS

C07 Malignant neoplasm of the parotid salivary gland

C08 Malignant neoplasm of other and unspecified large salivary glands

Excluded: malignant neoplasms of the specified small salivary glands, which are classified according to
with their anatomical localization malignant neoplasms of small salivary glands NOS (C06.9)
parotid salivary gland (C07)

C08.0 Submandibular gland. Submandibular gland
C08.1Sublingual gland
C08.8 The defeat of the large salivary glands, which goes beyond one or more of the above localizations.
Malignant neoplasm of the large salivary glands, which cannot be attributed to the site of origin
to none of the headings C07-C08.1
C08.9 Large salivary gland, unspecified. Salivary glands (large) NOS

C09 Malignant neoplasm of the tonsil

Excludes: lingual tonsil (C02.4)
pharyngeal tonsil (C11.1)

C09.0 Tonsil dimple
C09.1The arch of the palatine tonsil (anterior) (posterior)
C09.8The defeat of the amygdala, which goes beyond one or more of the above localizations.
C09.9 Tonsils, unspecified
Tonsils:
... NOS
... throat
... palatine

C10 Malignant neoplasm of the oropharynx

Excludes: tonsils (C09 .-)

C10.0Epiglottis fossa
C10.1The anterior surface of the epiglottis. Epiglottis, free border (edge). Lingual-supraglottic fold (s).
Excludes: epiglottis (area above the hyoid bone) NOS (C32.1)
C10.2 Lateral wall of the oropharynx
C10.3 The posterior wall of the oropharynx
C10.4Gill slits. Branchial cysts [localization of the neoplasm]
C10.8The defeat of the oropharynx, which goes beyond one or more of the above localizations.
Border zone of the oropharynx
C10.9Oropharynx, unspecified

C11 Malignant neoplasm of the nasopharynx

C11.0 The upper wall of the nasopharynx. The vault of the nasopharynx
C11.1 The posterior wall of the nasopharynx. Adenoid tissue. Pharyngeal tonsil
C11.2 Lateral wall of the nasopharynx. Rosenmüller pits. Eustachian tube openings. Pharyngeal pocket
C11.3 The anterior wall of the nasopharynx. The bottom of the nasopharynx. Nasopharyngeal (front) (back) surface of the soft palate.
Posterior margin of nasal:
... joan
... partitions
C11.8 Lesions of the nasopharynx that go beyond one or more of the above localizations.
C11.9 Nasopharynx, unspecified. Nasopharyngeal walls NOS

C12 Malignant neoplasm of the piriform sinus. Piriform fossa

C13 Malignant neoplasm of the lower part of the pharynx

Excludes: piriform sinus (C12)

C13.0 Cricoid region
C13.1 Cherpalonadlaryngeal fold of the lower part of the pharynx.
Cherpalonadal laryngeal fold:
... NOS
... marginal zone
Excludes1: scapular laryngeal fold of laryngeal part (C32.1)
C13.2 The posterior wall of the lower part of the pharynx
C13.8Lesion of the lower part of the pharynx that goes beyond one or more of the above localizations.
C13.9 Lower pharynx, unspecified. Walls of the lower part of the pharynx NOS

C14 Malignant neoplasm of other and ill-defined localizations of the lip, oral cavity and pharynx

Excludes: oral cavity NOS (C06.9)

C14.0Pharynx, unspecified
S14.1 Laryngopharynx
C14.2 Valdeyer's pharyngeal ring
C14.8A lesion of the lip, mouth and pharynx that goes beyond one or more of the above localizations.
Malignant neoplasm of the lip, oral cavity and pharynx, which, according to the place of origin, cannot be attributed to any of the C00-C14.2 headings.

Malignant neoplasms of the digestive organs (C15-C26)

C15 Malignant neoplasm of the esophagus

Note. Two alternative subclassifications are proposed:
.0- .2 by anatomical description
.3- .5 on thirds of the organ
This departure from the principle that rubrics should be mutually exclusive is deliberate since both terminological forms are used, but the anatomical regions highlighted are not similar.

C15.0 Cervical esophagus
C15.1 Thoracic esophagus
C15.2Abdominal esophagus
C15.3 The upper third of the esophagus
C15.4 Middle third of the esophagus
C15.5 Lower third of the esophagus
C15.8 Lesion of the esophagus that goes beyond one or more of the above localizations.
C15.9 Esophagus, unspecified

C16 Malignant neoplasm of the stomach

C16.0Cardia. Cardiac foramen. Cardioesophageal junction. Gastroesophageal junction. Esophagus and stomach
C16.1 Fundus of the stomach
C16.2 Body stomach
C16.3 The gatekeeper's entrance. Vestibules of the stomach
C16.4 The gatekeeper. Entrepreneur. Gatekeeper channel
C16.5 Lesser curvature of the stomach of the unspecified part. Lesser curvature of the stomach, not classified under
ricks С16.1-С16.4
C16.6 Greater curvature of the stomach of the unspecified part. Greater curvature of the stomach, not classified under
rickach С16.0-16.4
C16.8 The defeat of the stomach, going beyond one or more of the above localizations
C16.9Unspecified stomach. Carcinoma of the stomach NOS

C17 Malignant neoplasm of the small intestine

C17.0 Duodenal ulcer
C17.1 Jejunum
C17.2The ileum.
Excludes: ileocecal valve (C18.0)
C17.3 Meckel's diverticulum
C17.8 Lesion of the small intestine that goes beyond one or more of the above localizations.
C17.9 Small intestine, unspecified

C18 Malignant neoplasm of the colon

C18.0
C18.1 Vermiform appendix
C18.2 Ascending colon
C18.3 Hepatic flexure
C18.4 Transverse colon
C18.5 Splenic flexure
C18.6 Descending colon
C18.7Sigmoid colon. Sigmoid (bending).
Excludes: rectosigmoid junction (C19)
C18.8 The defeat of the colon, going beyond one or more of the above localizations.
C18.9 Colon, unspecified. Colon NOS

C19 Malignant neoplasm of the rectosigmoid junction.

Colon and rectum. Rectosigmoid (colon)

C20 Malignant neoplasm of the rectum. Ampoules of the rectum

C21 Malignant neoplasm of the anus [anus] and anal canal

C21.0Anus, unspecified
Excludes: anal section:
... edges (C43.5, C44.5)
... leather (C43.5, C44.5)
perianal skin (C43.5, C44.5)
C21.1Anal canal. Anal sphincter
C21.2 Cloacogenic zone
C21.8 The defeat of the rectum, anus [anus] and anal canal, extending beyond one or more
the above localizations. Anorectal connections. Anorectal area.
Malignant neoplasm of the rectum, anus [anus] and anal canal, which is in place
occurrence cannot be attributed to any of the headings C20-C21.2

C22 Malignant neoplasm of the liver and intrahepatic bile ducts

Excludes: biliary tract NOS (C24.9)
secondary malignant neoplasm of the liver (C78.7)

C22.0 Hepatic cell carcinoma. Hepatocellular carcinoma. Hepatoma
C22.1 Intrahepatic bile duct cancer. Cholangiocarcinoma
C22.2 Hepatoblastoma
C22.3Angiosarcoma of the liver. Kupffer cell sarcoma
C22.4 Other liver sarcomas
C22.7 Other specified liver cancers
C22.9 Malignant neoplasm of liver, unspecified

C23 Malignant neoplasm of the gallbladder

C24 Malignant neoplasm of other and unspecified parts

biliary tract

Excludes: intrahepatic bile duct (C22.1)

C24.0 Extrahepatic bile duct. Bile duct or passage NOS. Common bile duct.
Cystic duct. Hepatic duct
C24.1 Ampoules of the Vater papilla
C24.8 Damage to the biliary tract that goes beyond one or more of the above localizations.
Malignant neoplasm involving the intrahepatic and extrahepatic bile ducts.
Malignant neoplasm of the biliary tract, which at the site of origin cannot be attributed to any
from headings C22.0-C24.1
C24.9Biliary tract, unspecified

C25 Malignant neoplasm of the pancreas

C25.0 Pancreatic head
C25.1 Pancreas body
C25.2 Pancreatic tail
C25.3 Pancreatic duct
C25.4Islet cells of the pancreas. Islets of Langerhans
C25.7 Other parts of the pancreas. Pancreatic neck
C25.8 Damage to the pancreas that goes beyond one or more of the above localizations.
C25.9 Pancreas, unspecified

C26 Malignant neoplasm of other and ill-defined digestive organs

Excludes: peritoneum and retroperitoneal space (C48.-)

C26.0Intestinal tract, unspecified Intestinal NOS
C26.1 Spleen
Excludes: Hodgkin's disease (C81 .-)
non-Hodgkin lymphoma (C82-C85)
C26.8The defeat of the digestive system, going beyond one or more of the above localizations.
Malignant neoplasm of the digestive system, which cannot be attributed to either
to one of the headings С15-С26.1
Excludes: cardioesophageal junction (C16.0)
C26.9Inaccurately marked localizations within the digestive system.
Alimentary canal or tract NOS. Gastrointestinal tract NOS

Malignant neoplasms of the respiratory organs

AND BREAST CELL (C30-C39)

Included: middle ear
Excludes: mesothelioma (C45 .-)

C30 Malignant neoplasm of the nasal cavity and middle ear

C30.0 The nasal cavity. Cartilage of the nose. Conchs are nasal. The inside of the nose. Septum of the nose. Vestibules of the nose.
Excludes: nasal bones (C41.0)
nasal NOS (C76.0)
olfactory bulb (C72.2)
posterior edge of nasal septum and choanalis (C11.3)
skin of the nose (C43.3, C44.3)
C30.1 Middle ear. Eustachian tube. Inner ear. Mastoid cells.
Excludes: ear canal (external) (C43.2, C44.2)
ear (meatus) bones (C41.0)
ear cartilage (C49.0)
skin of the (outer) ear (C43.2, C44.2)

C31 Malignant neoplasm of the paranasal sinuses

C31.0 Maxillary sinus. Sinuses (maxillary) (maxillary)
C31.1 Ethmoid sinus
C31.2 Frontal sinus
C31.3Sphenoid sinus
C31.8The defeat of the paranasal sinuses, going beyond one or more of the above localizations.
C31.9 Paranasal sinus, unspecified

C32 Malignant neoplasm of the larynx

C32.0The actual vocal apparatus. The larynx itself. Vocal fold (true) NOS
C 32.1 Above the actual vocal apparatus. Laryngeal folds of the larynx.
Epiglottis (participant above the hyoid bone) NOS. Extra-laryngeal part. False vocal folds.
The posterior (laryngeal) surface of the epiglottis. Ventricular folds of the larynx.
Excludes: anterior surface of epiglottis (C10.1)
scapular laryngeal fold:
... NOS (C13.1)
... lower pharyngeal part (C13.1)
... marginal zone (C13.1)
C32.2 Under the actual vocal apparatus
C32.3Laryngeal cartilage
C32.8 The defeat of the larynx, which goes beyond one or more of the above localizations.
C32.9 Larynx, unspecified

C33 Malignant neoplasm of the trachea

C34 Malignant neoplasm of bronchi and lung

C34.0 The main bronchi. Carina of the trachea. Lung root
C34.1 Upper lobe, bronchi, or lung
C34.2Middle lobe, bronchi, or lung
C34.3 Lower lobe, bronchi, or lung
C34.8 Damage to the bronchi or lung, which goes beyond one or more of the above localizations.
C34.9 Bronchus or lung, unspecified

C37 Malignant neoplasm of the thymus

C38 Malignant neoplasm of heart, mediastinum and pleura

Excludes: mesothelioma (C45 .-)

C38.0Hearts. Pericardium.
Excludes: large vessels (C49.3)
C38.1 Anterior mediastinum
C38.2Posterior mediastinum
C38.3 Mediastinum, unspecified
C38.4 Pleura
C38.8Damage to the heart, mediastinum and pleura, going beyond one or more of the above localizations.

C39 Malignant neoplasm of other and ill-defined

localizations of the respiratory and intrathoracic organs

Excludes: intrathoracic NOS (C76.1)
chest NOS (C76.1)

C39.0Upper respiratory tract, unspecified
C39.8The defeat of the respiratory system and intrathoracic organs, which goes beyond one or more of the above localizations. Malignant neoplasm of the respiratory and intrathoracic organs, which at the place of origin cannot be attributed to any of the C30-C39.0 headings
C39.9Inaccurately marked localizations within the respiratory system. Respiratory tract NOS

Malignant neoplasms of bones and articular cartilage (C40-C41)

Excludes: bone marrow NOS (C96.7)
synovium (C49.-)

C40 Malignant neoplasm of bones and articular cartilage of extremities

C40.0
C40.1
C40.2
C40.3
C40.8 The defeat of the bones and articular cartilage of the extremities, going beyond one or more of the above localizations.
C40.9 Bones and articular cartilage of an unspecified limb

C41 Malignant neoplasm of bones and articular cartilage of other and unspecified sites

Excludes: bones of limbs (C40 .-)
cartilage:
... ear (C49.0)
... larynx (C32.3)
... limbs (C40 .-)
... nose (C30.0)

C41.0
odontogenic:
... maxillary sinus (C31.0)
... upper jaw (C03.0)
jaw (lower) bony part (C41.1)
C41.1 Lower jaw. The lower jaw is the bony part.
Excludes: carcinoma of any type other than intraosseous or
odontogenic:
... jaw NOS (C03.9)
... lower (C03.1)
upper jaw bone (C41.0)
C41.2 Vertebral column.
Excludes: sacrum and coccyx (C41.4)
C41.3 Ribs, sternum and collarbone
C41.4 Bones of the pelvis, sacrum and coccyx
C41.8 Damage to bones and articular cartilage that goes beyond one or more of the above localizations.
Malignant neoplasm of bones and articular cartilage, which cannot be attributed to either
to one of the headings С40-С41.4
C41.9Bone and articular cartilage, unspecified

Melanoma and other malignant neoplasms of the skin (C43-C44)

C43 Malignant melanoma of the skin

Included: morphological codes M872-M879 with a code of the nature of the neoplasm / 3
Excludes1: malignant melanoma of genital skin (C51-C52, C60.-, C63.-)

C43.0 Malignant lip melanoma.
Excludes: red border of lip (C00.0-C00.2)
C43.1 Malignant melanoma of the eyelid, including adhesions of the eyelids
C43.2 Malignant melanoma of the ear and external auditory canal
C43.3Malignant melanoma of other and unspecified parts of the face
C43.4Malignant melanoma of the scalp and neck
C43.5 Malignant melanoma of the trunk.
Anal department:
... the edges
... skin
Excludes: anus [anus] NOS (C21.0)
C43.6 Malignant melanoma of the upper limb, including the shoulder area
C43.7 Malignant melanoma of the lower extremity, including the area of \u200b\u200bthe hip joint
C43.8 Malignant melanoma of the skin that goes beyond one or more of the above localizations.
C43.9 Malignant melanoma of the skin, unspecified. Melanoma (malignant) NOS

C44 Other malignant neoplasms of the skin

Includes: malignant neoplasms:
... sebaceous glands
... sweat glands
Excludes: Kaposi's sarcoma (C46.-)
malignant melanoma of the skin (C43 .-)
genital skin (C51-C52, C60.-, C63.-)

C44.0 Lip skin. Basal cell carcinoma of the lip.
Excludes: malignant neoplasms of the lip (C00. -)
C44.1 Eyelid skin, including eyelid adhesions.
C44.2 .
Excludes: connective tissue of ear (C49.0)
C44.3
C44.4
C44.5 Torso skin.
Anal department:
... the edges
... skin
Perianal skin. Breast skin.
Excludes: anus [anus] NOS (C21.0)
C44.6
C44.7
C44.8 Skin lesions that go beyond one or more of the above localizations.
C44.9 Malignant neoplasms of skin, unspecified area

Malignant neoplasms of mesothelial and soft tissues (С45-С49)

C45 Mesothelioma

Includes: morphological code M905 with a code of the nature of the neoplasm / 3

C45.0 Pleural mesothelioma.
Excludes: other malignant neoplasms of the pleura (C38.4)
C45.1Peritoneal mesothelioma. Mesentery. Colon mesentery. Oil seal. Peritoneum (parietal, pelvic).
Excludes: other malignant neoplasms of the peritoneum (C48 .-)
C45.2 Pericardial mesothelioma.
Excludes: other malignant neoplasms of the pericardium (C38.0)
C45.7 Mesothelioma of other localizations
C45.9 Mesothelioma, unspecified

C46 Kaposi's sarcoma

Included: morphological code M9140 with the character code of the neoplasm
education / 3

C46.0 Kaposi's sarcoma of the skin
C46.1 Kaposi's sarcoma of soft tissues
C46.2 Palate Kaposi's sarcoma
C46.3 Kaposi's sarcoma of the lymph nodes
C46.7 Kaposi's sarcoma of other localizations
C46.8 Kaposi's sarcoma of multiple organs
C46.9 Kaposi's sarcoma, unspecified

C47 Malignant neoplasm of peripheral nerves and autonomic nervous system

Includes: sympathetic and parasympathetic nerves and ganglia

C47.0Peripheral nerves of the head, face and neck.
Excludes: orbital peripheral nerves (C69.6)
C47.1 Peripheral nerves of the upper limb, including the area of \u200b\u200bthe shoulder girdle
C47.2 Peripheral nerves of the lower limb, including the hip region
C47.3 Peripheral nerves of the chest
C47.4 Peripheral nerves of the abdomen
C47.5 Peripheral nerves of the pelvis
C47.6 Peripheral nerves of trunk, unspecified
C47.8 Damage to the peripheral nerves and the autonomic nervous system, which goes beyond one or more of the above localizations.
C47.9 Peripheral nerves and autonomic nervous system, unspecified

C48 Malignant neoplasm of the retroperitoneal space and peritoneum

Excludes: Kaposi's sarcoma (C46.1)
mesothelioma (C45 .-)

C48.0 Retroperitoneal space
C48.1 Refined parts of the peritoneum. Mesentery.
Mesentery of the transverse colon. Oil seal. Peritoneum:
... parietal
... pelvic
C48.2Peritoneum, unspecified
C48.8The defeat of the retroperitoneal space and peritoneum, which goes beyond one or more of the above localizations.

C49 Malignant neoplasm of other types of connective and soft tissues

Included: blood vessel
joint capsule
cartilage
fascia
adipose tissue
ligaments other than uterine
lymphatic vessel
muscle
synovium
Excludes: cartilage:
... articular (C40-C41)
... larynx (C32.3)
... nose (C30.0)
connective tissue of the breast (C50 .-)
Kaposi's sarcoma (C46 .-)
mesothelioma (C45 .-)
peritoneum (C48.-)
retroperitoneal space (C48.0)

C49.0 Connective and soft tissues of the head, face and neck.
Connective tissue:
... ear
... century
Excludes: orbital connective tissue (C69.6)
C49.1Connective and soft tissues of the upper limb, including the area of \u200b\u200bthe shoulder girdle
C49.2 Connective and soft tissues of the lower limb, including the hip region
C49.3 Connective and soft tissues of the chest. Armpit. Diaphragms. Large vessels.
Excludes: breast (C50 .-)
heart (C38.0)
mediastinum (C38.1-C38.3)
C49.4 Connective and soft tissues of the abdomen. Abdominal wall. Hypochondrium areas
C49.5 Connective and soft tissues of the pelvis. Buttocks. Groin area. Perineum
C49.6 Unspecified connective and soft tissues of the trunk. Backs NOS
C49.8Damage to the connective and soft tissues that goes beyond one or more of the above localizations.
Malignant neoplasm of connective and soft tissues, which cannot be at the place of origin
assigned to any of the headings C47-C49.6
C49.9 Unspecified connective tissue and soft tissue

Malignant neoplasm of the breast (C50)

C50 Malignant neoplasm of the breast

Includes: connective tissue and breast
Excludes: skin of mammary gland (C43.5, C44.5)

C50.0 Nipple and areola
C50.1 Central part of the breast
C50.2 Upper-inner quadrant of the breast
C50.3 Inferior quadrant of the breast
C50.4 Upper-outer quadrant of the breast
C50.5 Lower-outer quadrant of the mammary gland
C50.6 Axillary back of the breast
C50.8 Breast lesion that goes beyond one or more of the above localizations
C50.9 Breast, unspecified

Malignant neoplasms of the female genital organs (С51-С58)

Includes: female genital skin

C51 Malignant neoplasm of the vulva

C51.0Large pudendal lips. Bartholin's (large gland of the vestibule) gland
C51.1Small pudendal lip
C51.2 Clitoris
C51.8 Lesion of the vulva that goes beyond one or more of the above localizations.
C51.9 Vulva, unspecified. Female external genital organs NOS. Shame area

C52 Malignant neoplasm of the vagina

C53 Malignant neoplasm of the cervix

C53.0 Inner part
C53.1 Outer part
C53.8 Lesion of the cervix, which goes beyond one or more of the above localizations.
C53.9

C54 Malignant neoplasm of the body of the uterus

C54.0 Isthmus of the uterus. Lower segment of the uterus
C54.1 Endometrium
C54.2 Myometrium
C54.3 Fundus of uterus
C54.8 Damage to the body of the uterus that goes beyond one or more of the above localizations.
C54.9 Uterine body, unspecified location

C55 Malignant neoplasm of uterus, unspecified site

C56 Malignant neoplasm of the ovary

C57 Malignant neoplasm of other and unspecified female genital organs

C57.0 Fallopian tube. Oviduct. Fallopian tube
C57.1Broad ligament
C57.2 Round ligament
C57.3 Parametry. Uterine ligaments NOS
C57.4Uterine appendages, unspecified
C57.7Other specified female genital organs. Wolf body or duct
C57.8 The defeat of the female genital organs, which goes beyond one or more of the above localizations.
Malignant neoplasm of the female genital organs, which cannot be attributed to the place of origin
to none of the headings C51-C57.7, C58. Tubal-ovarian. Utero-ovarian
C57.9 Female genital organs of unspecified localization. Genitourinary tract in women NOS

C58 Malignant neoplasm of the placenta. Chorionic carcinoma NOS. Chorionepithelioma NOS

Excludes1: chorionadenoma (destructive) (D39.2)
cystic drift:
... NOS (O01.9)
... invasive (D39.2)
... malignant (D39.2)

Malignant neoplasms of male genital organs (C60-C63)

Included: male genital skin

C60 Malignant neoplasm of the penis

C60.0Foreskin. Preputium
C60.1 Glans of the penis
C60.2The body of the penis. Cavernous body
C60.8 Penile lesion that goes beyond one or more of the above localizations.
C60.9 Penis of unspecified localization. Penile skin NOS

C61 Malignant neoplasm of the prostate

C62 Malignant neoplasm of testicle

C62.0An undescended testicle. Ectopic testis [localization of the neoplasm].
Retained testicle [localization of neoplasm]
C62.1 Descended testicle. The testicle in the scrotum
C62.9 Testicle, unspecified

C63 Malignant neoplasm of other and unspecified male genital organs

C63.0Epididymis
C63.1 Spermatic cord
C63.2 Scrotum. Scrotal skin
C63.7 Other specified male genital organs. Seminal vesicles. Testicular sheath
C63.8 The defeat of the male genital organs, going beyond one or more of the above localizations.
Malignant neoplasm of the fly genital organs, which cannot be attributed to the place of origin
to none of the headings C60-C63.7
C63.9 Male genital organs of unspecified localization. Genitourinary tract in men NOS

Malignant neoplasms of the urinary tract (C64-C68)

C64 Malignant neoplasm of the kidney, other than the renal pelvis

Excluded: renal:
... cups (C65)
... pelvis (C65)

C65 Malignant neoplasm of the renal pelvis

Ureteropelvic junction. Renal cups

C66 Malignant neoplasm of the ureter

Excludes: ureteral orifice of urinary bladder (C67.6)

C67 Malignant neoplasm of the bladder

C67.0 Bladder triangle
C67.1 Bladder domes
C67.2 Lateral wall of the bladder
C67.3 Anterior wall of the bladder
C67.4 Back wall of the bladder
C67.5Bladder neck. Internal urethral opening
C67.6Ureteral foramen
C67.7 Primary urinary duct (urachus)
C67.8Damage to the bladder that goes beyond one or more of the above localizations.
C67.9Bladder, unspecified

C68 Malignant neoplasm of other and unspecified urinary organs

Excludes: genitourinary tract NOS:
... in women (C57.9)
... in men (C63.9)

C68.0Urethra.
Excludes: urethral orifice of bladder (C67.5)
C68.1Paraurethral glands
C68.8 Damage to the urinary organs that goes beyond one or more of the above localizations.
Malignant neoplasm of the urinary organs, which, according to the place of origin, cannot be attributed to any of the headings C64-C68.1
C68.9 Urinary organs, unspecified. Urinary system NOS

Malignant neoplasms of the eye, brain

AND OTHER DEPARTMENTS OF THE CENTRAL NERVOUS SYSTEM (С69-С72)

C69 Malignant neoplasm of the eye and its adnexa

Excludes: connective tissue of eyelid (C49.0)
eyelids (skin) (C43.1, C44.1)
optic nerve (C72.3)

C69.0 Conjunctiva
C69.1 Cornea
C69.2 Retinas
C69.3 Choroid
C69.4The ciliary [ciliary] body. Eyeball
C69.5 Lacrimal gland and duct. Lacrimal sac. Lacrimal duct
C69.6 Eye sockets. Connective tissue of the orbit. External ocular muscle. Peripheral nerves of the orbit.
Retrobulbar tissue. Retroocular tissue.
Excludes: orbit bones (C41.0)
C69.8The defeat of the eye and its accessory apparatus, going beyond one or more of the above localizations.
C69.9 Eyes, unspecified

C70 Malignant neoplasm of the meninges

C70.0 Meninges
C70.1 Spinal cord membranes
C70.9

C71 Malignant neoplasm of the brain

Excludes: cranial nerves (C72.2-C72.5)
retrobulbar tissue (C69.6)

C71.0 The large brain, except for the lobes and ventricles. Corpus callosum. Above the brain outline NOS
{!LANG-2000e481f49be1fb4ea76b464062bc9f!}{!LANG-c347b14f1d6dd14273bbedb617fa1f5f!}
{!LANG-60231b3d1104f113afe71535fdf72f40!}{!LANG-d00c9e1c8dcb51658adbf798ed714283!}
{!LANG-5dd158f85bc6066cb497eacca0eedb2c!}{!LANG-a5d15cd237e41b3628d5cfefb39d1755!}
{!LANG-86684246a8d1fa4eba99e0153e106aa1!}{!LANG-6ab385bf761d871f7f0c4d053ad5f355!}
{!LANG-79c82c1d9a4028875815a06ded5aab39!}{!LANG-cd029ba79bbd7578ac1e1dcc85669afd!}
{!LANG-f0912c1385959d6d224ead5d213b9947!}
{!LANG-56c735470fa50e3554b3ea8272d7abd1!}{!LANG-2a91ec8e9604d17e27b776b9b7816f35!}
{!LANG-bfaf65b7c729378cd840a1d181f23c12!}{!LANG-562f506d743f24d1eddd0e2ca3ea20e1!}
{!LANG-8e61cea3627fd1a91f69d165600d1ae3!}{!LANG-8f406309c3a41fff36a965b73da1ae37!}
{!LANG-2c3bdfd223e2bc1e8d51730c51976651!}{!LANG-240ed090d0ac7fac1c599b08943382a5!}

{!LANG-85bd177e8fe348dad74724d021c950de!}

{!LANG-e52fd3edc57cc213c309f7ed14024ec8!}

{!LANG-a4da8aea16380574a10804b39bb019c1!}
{!LANG-b25b3051443eba432993ad8dad194b62!}

{!LANG-0429fd5ca8421cc903db679bc6ae2610!}{!LANG-6057791fe9f2a828f8b10edf28620d0b!}
{!LANG-f8524ccfc34fb8b01a2920e06e9a1d13!}{!LANG-5b2ad53f723290219a49598189603658!}
{!LANG-41db8422eb72ae8f7ad5e2d43d3c882b!}{!LANG-37272fe15ac4abfb18321191da75c61c!}
{!LANG-97a416c7a6ace2d28502c4b918b99054!}{!LANG-80222868025f2fdd91928d9eae00b45b!}
{!LANG-dd4688e82529d1a2bd3b1cf00b79a5f6!}{!LANG-7fd22c2ff503646f41455274d338f59e!}
{!LANG-eefbbe5c35a5de99d0d3f5ee2e58ce35!}{!LANG-997da822bab0c836db4b76e505d7ceb9!}
{!LANG-2294223e26d3176ca9d378677df55b33!}{!LANG-921496451c0c1e76d632cff7017a1982!}
{!LANG-5e80601c8ea89e01892e3dbdb7c48343!}
{!LANG-184e7ce92257823de3e20c720332746b!}
{!LANG-cd183e41cdb5da9310377ca592337ffa!}
{!LANG-bb177400ee2bde3f9ec7dc7d205350d9!}{!LANG-637dfab545de5316944924561e2ae63e!}

{!LANG-ebc6cc5c97b9a68da735e24d5a7a77cd!}

{!LANG-d61a7d6eab24397bc48f04aaa9fdc874!}

{!LANG-2d020041fb52620a0624c8436b5c40f0!}

{!LANG-19052f42d7af4b6607d594252d517e37!}

{!LANG-9ddeb1f37f42b8e04ca359694e8dd4c0!}{!LANG-f6caaabdc54401dee7cdd8592a5eaecb!}
{!LANG-061bfbef9223aa50136f5f8c9c80c17d!}{!LANG-90fad261ced2b6a02dd3aedab54c2d2d!}
{!LANG-c079a8fa6ac0b344c3e6d6a9ff6ff2c0!}{!LANG-81ff28433a7b3f04d633c927aa513603!}

{!LANG-60180a92db10efb45c79949f835b30cf!}

{!LANG-58723f0d6b7a84085435ebfeea2a98b5!}
{!LANG-c8dacb618548e4f0752232fdd7371eb3!}
{!LANG-4f89e65491c000b3492cb5f2e3fa825c!}
{!LANG-7fc081b532fa888e8bdc3e89a9e6c549!}
{!LANG-4b7c4661d71103b2467f5cac54aca52e!}
{!LANG-e6b5513ef3d63c2ce55b5ef8ed384e38!}

{!LANG-25cb6ab2285935a30fe945f8a6868f82!}
{!LANG-f1cf02a121936e96bb6c5c7b942c3564!}{!LANG-b78907f3aaae3042ed398490817f20ca!}
{!LANG-2fe9ed4518e82a1839c551d1247b1bf9!}{!LANG-95b18d00a06a53469fd33daeca715553!}
{!LANG-f19a098cce050f57dc442ba6812fab6f!}{!LANG-b3acc5ec9d564f944454288a9b9b37b3!}
{!LANG-bfed448564d8e38746541f399e1dc4c6!}{!LANG-b08c7eb240a79c768089c6452d13ebf6!}
{!LANG-78aade70277397474a31c1becd8c1bd2!}
{!LANG-fbc87db2602331688a1f5e10c7eaeac8!}{!LANG-802946ab6531ce61a8384ebc9893f528!}
{!LANG-e5c0439129a4ca43fb7ddfb2bd2e0bfc!}
{!LANG-1d1532bc072bd077d170c6240afe9630!}

{!LANG-ce7438eea859b23e12259ce72d56858b!}

{!LANG-c5840acc8239ee78d30e0f9f0efbf0a3!}

{!LANG-b6b1a614ea2c598b08437e0de98cc837!}

{!LANG-58c6016265565d899b95bf55dc698708!}
{!LANG-2617345bde2aa1d1c18f22edf98f8de3!}
... in women (C57.9)
... in men (C63.9)
{!LANG-a50eae31397ea8812d733d4e432df757!}
{!LANG-344a814756f859aabfd25a162f895d8d!}

{!LANG-5b24dfa745823c0a62fa74578a4ebbf5!}{!LANG-ea0ddd0391ffc2ab86fd4fd519f0f733!}
{!LANG-56f3e45121d94744c2133eea47877939!}{!LANG-61b3954a3d79e2c13e4235d46121a73e!}
{!LANG-ec319add7facab5851f232d5caad5330!}{!LANG-f03fee272382db5a6deb995be0d39cd1!}
{!LANG-11d9c44a499a2c9113a66a7c730735ba!}{!LANG-f292d5054a287a4bcf2f0a33e48bad0a!}
{!LANG-b71b78f7d877e7998d09db4f11060594!}
{!LANG-f297fd5a2782a3d6e660c09934164591!}
{!LANG-99d0379337b7c289b12ad493b2999f01!}
{!LANG-956a635be98603c179bce568a241d5fd!}{!LANG-3948af8eece7336bfa8158d50b710093!}
{!LANG-6c0ffbf8bd680f14585242051ff189e2!}{!LANG-ec3554ebbd812cc3fc6dbc66ab9cd8c5!}
{!LANG-297fa7c87e730231a52da1680263f22c!}{!LANG-648d86310f483b0c761663475a107a9c!}
{!LANG-9f8b641730857ead3a26e8b639b27573!}{!LANG-de58b9590909150d0e3c2d3d2b6efa47!}

{!LANG-908ec17673b820bbcc7bfbd373daa86e!}

{!LANG-aec2c90cd801c699a909bc2e1eb8bf3f!}

{!LANG-051b6c524846e1f974be4ed7e7a7d204!}{!LANG-89991e91646ae67f484a2845ff814b41!}
{!LANG-aa818375b50bc098bf10abff96241001!}{!LANG-b42894bcb897aa0a37d82eff15689ff9!}
{!LANG-5a4a44572ccf7def8aa25606a5333fed!}{!LANG-1fc47c2f7356324bac42c7d1f51eb96b!}
{!LANG-963eb33ddfc2c0ddc5dde7553f6204e8!}{!LANG-29403e063eb68cb2514c464504fc6b35!}
{!LANG-0891d5a62e6d10e9cecfc12f80ab7c45!}{!LANG-d6078c286ef0ae389275c1fcecd462d4!}
{!LANG-e61b4346de016cc6e8176ea14416bcc1!}{!LANG-fe5ae1da45fac6006970e2baaeddb99f!}
{!LANG-b3b674c2367b215966a1bbf8738cc0cb!}{!LANG-56898e9a1a82be5c05eba5e402b50d59!}
{!LANG-a6b379cde9ce199673c9ac60091f095c!}{!LANG-a36397b5e50a08c14e9aade3af522d19!}

{!LANG-fa428aea12d298d95dd1403508668c54!}

{!LANG-1cda4fae8ed9542ddbce7f011bd55c86!}{!LANG-59b71beec41244a905a17ff50863baaf!}
{!LANG-eed9994700d8a7b357b326dee3693e71!}{!LANG-992c4c3b1741a0b81eda3cb667528970!}
{!LANG-c9bbe2c732a8ec9d78e1717abf0886d1!}{!LANG-bbd9a96d6067ebd7ec6a78af7a37c187!}
{!LANG-42b616436b8e7549d45ac24de5260327!}{!LANG-63523f377dff9a0573662c71448ae4bf!}
{!LANG-aad70cd89e0b78bde2dbdc2e3dc278a6!}{!LANG-c52f4df82bbb0dabcb3a49b2e4cb06e0!}
{!LANG-d0bcb58149d1a0265606b3055491d522!}{!LANG-9a734187efba089955d70540f8443a48!}
{!LANG-8247febbe8db234c411289ff7f131772!}{!LANG-e7f486409ff04547c431972d2e8430f3!}
{!LANG-e2bd0d15cb820f40d6034c2af3b5e8df!}{!LANG-84ef3b33d59a6ec46352772f4c7c9691!}
{!LANG-88e0a05737f5744cbaf2aa1e6aabdef3!}{!LANG-9f95668086ea27ee9b0e81b7bd784afe!}

{!LANG-ae330bc387f9b7983b7811970fb9d898!}

{!LANG-32034ed701bd78afa8f64a26f5dbee63!}{!LANG-3f68be65f3ea4df116bed7a8cf0d72e1!}
{!LANG-c9a1ca6dfa894a005e76df0d86bb5a6d!}{!LANG-e54a7761bcdf904ce9942f4e43eaa5f7!}
{!LANG-4243b3ff2e1396c1ceeee49e345cb23e!}{!LANG-f7dc2fd5435a52b5b08f2876e0ac9f2d!}
{!LANG-4432d4463605e8e274b25f34613fc47e!}{!LANG-0254946296f1a6509da117cb7e158171!}
{!LANG-771d7e78634142a90736d0fa78bb24fe!}{!LANG-15105e6a0355a34fb555144f0c85390c!}
{!LANG-d4f3edad1a3eec81e75b242306934a59!}{!LANG-3b1daf8093d2ff42728594cb887163ae!}
{!LANG-8bb4fa75d73a157ccc50b65630e58077!}{!LANG-139bc783cfcd7cec2e7236537eaf781f!}
{!LANG-5bf9b95dbcc9e8344a80fe556aa59c1f!}{!LANG-ca9194d6eaa9fe566a61f1d1d39c5e5c!}
{!LANG-fe34490f9c9317a9bad8fa76b207daaa!}{!LANG-7dee9b7f8a2401c6c1073174024da63f!}

{!LANG-6473ebc097d9754ecbb8accbd47923b1!}

{!LANG-d29eac287dcf0f80d2a9ac1a6685eaa9!}
{!LANG-ec1fec44bc5a65f6461e79ed00914b36!}
{!LANG-a0b6226881b34a7d3f44dfdeed90c64a!}
{!LANG-1d7f614738c8895b6acfef4ab514ed7d!}
{!LANG-a8696e76ff8076b020d4163a15cc3c64!}
{!LANG-1fbc5521639cd8b59d5db2d73fadbe4f!}
{!LANG-1210d38c6aa95d99418ef40be8df4c14!}
{!LANG-8370cb155bf60361ca723b397d065ada!}
{!LANG-65131b917762a78245256a2860191a15!}
{!LANG-9fc949ed0b5a94b0c0b0ef8a6f44e59d!}

{!LANG-3cb6092b59a62c24f18738470afedc07!}

{!LANG-d750d1d8ee9c9afb25f32aa8648abe2a!}

{!LANG-f0135b75ef2c2b9815a8ec93ba2fdea9!}
{!LANG-efe33e3fa44758d1fa0fca9239743708!}
{!LANG-96a091710bd6bb085a9d6483c283d3da!}

{!LANG-f6dc81f7a773f7126affdbfa36207e22!}

{!LANG-f026bdf393b155fd9e24e719fd6b4d6c!}

{!LANG-51efe2485a5ac0c0c1f9207db236986e!}{!LANG-48462f59f80b30003555beefd316f397!}
{!LANG-50119c07e3615f2597113cb2866de77a!}{!LANG-d9e1397ee13416f9e83b0a8dff866b68!}
{!LANG-d4c74c8f04ce7fcf9bdc6466a44c8ab9!}{!LANG-6df93e3ac8ddcd22e250ca205f559ec0!}
{!LANG-e714ef2fb7c065ef2353f5cc98fe6c2a!}{!LANG-be3d0a6182ebd0ab94ed12edce46f6ba!}
{!LANG-4e047a2e1074c7cc25b2e6c3cebe28c0!}{!LANG-70c1a29c90769c6b5604985069fa1ab2!}
{!LANG-b04ce1575c6dae4e61bf8b1c0819c144!}{!LANG-91568e098fd25542ac51065fe521b690!}

{!LANG-efbaf20cb03d81a94325cfe9268709f8!}

{!LANG-aba22665f57298c3d1d0c4edb108a4fc!}

{!LANG-71b456ab04e4f996531854f0b1297ed8!}{!LANG-3150875c6cef03ff33ddbe0374f21366!}
{!LANG-f6e352d86072179d19b4f7a34905a144!}{!LANG-d3c29b6a05beecf223ca815919d7375e!}
{!LANG-4bb463a934303e742ac0aa3bd83dc822!}{!LANG-8bb5a251328d3932a9bfbb0c8115a4d1!}
{!LANG-f3833ce76ef368210e2cadc434fbcdce!}{!LANG-e3533341dfedbee2e94a5e05ca2e5a8b!}
{!LANG-bd6394444fcb4a6af79382faa65bb684!}{!LANG-9aa6dddfd5110886b40fcee5c5cb63e0!}

{!LANG-890304040216e0a0c237b9fbd58abd98!}

{!LANG-0a7dab4a431c38f0b279c673a9bbef8f!}

{!LANG-60f2ecfa85cc2e0123141aa88739405e!}{!LANG-be0f0ab922d0fcbbdc7199ce7ef73f9d!}
{!LANG-b8fca3654723de122ce343f93ed094db!}{!LANG-8eb153fec27283e30a9a626bae9d6f69!}
{!LANG-33af6de5dae81759c0740bb8c76ce2c6!}{!LANG-961203cf51e13c5082f38795638217c7!}
{!LANG-6e2f89e413b7b1069380f1dd0cc7ed01!}{!LANG-ab574461f19ab24f358afc816d7d4ce5!}
{!LANG-2afa3ec52d43586badb4ed41e9e68e82!}{!LANG-b1fc52e99509656f678538a10f4344d7!}
{!LANG-60b75351ac1e8cc44b237c1bed547e61!}{!LANG-7287b48c255bd3268ac1ccc7438d7ec5!}
{!LANG-aab713a1d5a296a56dea8a9ebf7389d2!}{!LANG-b94b5c8266d9ad33409ef24ecaa7c56b!}
{!LANG-9a5b31deed1d982f788f84b535121110!}{!LANG-5007ea40dca63035f9f6615de431e829!}
{!LANG-d43e62ada25faed1fdce666060730b95!}{!LANG-19b7a58c8ea2f323a6abbbd64e1e8f95!}
{!LANG-2eae073a5fd66d35df4b2a5ab10f2d73!}{!LANG-19e75cfeb9bc3f1b36917e74861b85ea!}

{!LANG-20bcc482a7de67b0c858ceb421314066!}

{!LANG-4e9a98e91bf5104ed6b24ae0e8186adb!}

{!LANG-b704f07d330a828a5a0e0b69cafcbb47!}{!LANG-19b344df3ec35fe0eaeec6a08b38bdcc!}
{!LANG-29917910cd9e16ad3aa6e8983a660057!}{!LANG-514c2b9d41e4f7cf4c383be7feb2e8b7!}
{!LANG-8b782716b3acb06ff452e262b5ceb43c!}{!LANG-e74c4150dbdd08771a4aeb8d1d22742f!}
{!LANG-d9b68025c639c904e29971f9ecb48a5d!}{!LANG-556a3497a7fad0302e8db412c73cd2f7!}
{!LANG-2d9af8d6ebb97c125d05df7cc2f29f77!}{!LANG-b5faddc95c2a026d6cc61435ce2846dd!}
{!LANG-af294f2f9dc18be148cbfb942c6a0985!}{!LANG-ff987413ce303fdbda885693ad47fb86!}
{!LANG-571e01d61c53f9f819a601cd26b9fe97!}

{!LANG-21edee6da858a2cdfb826b38119b13d3!}

{!LANG-ef57732a7bb1a210316681c1edbdae90!}

{!LANG-cc93c412610ca6532c3148fa1b2d7c72!}{!LANG-14f91165a471cc02fbf9c5219014d98c!}
{!LANG-fbefe20d52ae9338cf142e546f447411!}{!LANG-841fcce34b3fadc8d5323cf62e9b4156!}
{!LANG-852373ee92b0ee09930ce9ef2234099c!}
{!LANG-80c777c1b59b01e223b16609f0981c2a!}{!LANG-a95e1bc807f8f1a367bc539ed71f419d!}
{!LANG-4a71f48ad480b3473229a7793604f769!}
{!LANG-46421acb3f34d8f89d226c67d8e44cb1!}
{!LANG-5d8de9e103cfdaac9e8495ce7b2bda7b!}
{!LANG-125ac002790af17a62a0a753bf48a25e!}
{!LANG-32fafa3c3ceadd36a92b2ab3ec02cd8c!}{!LANG-860404dca2797e456cb9463b8eb64d5a!}

{!LANG-254e048dc64ce72a4e3033330b7420ef!}

{!LANG-d3ede7dbc655ffb34124c4f7fe5fc43c!}

{!LANG-4d0fdf28e00b38eede4d2be9df67aed1!}{!LANG-a1c8b10ae412b89df74a255a124e3329!}
{!LANG-bfd9fab1e0e31b43d22f86556dad1753!}{!LANG-0414b8b33ab4249af50209e33c1219eb!}
{!LANG-1d62c955d5e2dd11f910025b6d180cf7!}{!LANG-5e91f35679468f74a5851e8b2a79acb9!}
{!LANG-3941729d1a431f3b06ad1d7e2d632d1a!}{!LANG-ab829f6a67ddf200c295566dd1eef24e!}
{!LANG-e4de8185f18bed750a5210ae1de47a1c!}{!LANG-10c2d4fba9e0ecb91b07aa497f666b94!}
{!LANG-5083e5bab19d4ad583b114a3f37c2f64!}{!LANG-5a5d2b01806da96166487589ae0a3f6f!}

{!LANG-e1c28d30e39e53e530e16fa8264b7a81!}

{!LANG-036d573b3dbb25d9076fc827e8e18ac9!}

{!LANG-4f6e9685ad51994c71c3112448b95e70!}{!LANG-621b4d1ea38c08b5ba7876d2bf683540!}
{!LANG-15452debfbef5b9e3b4f9a4612adb3b6!}
{!LANG-23d545df8fbfdc666e49e279ee637ccc!}{!LANG-b8ac93ebca90ad8a628f42bdaef8443d!}
{!LANG-dcc33c0e88033943d2548fbf96d9f445!}{!LANG-69403415da47408707977676442be991!}
{!LANG-121a900f4dc0497c0381fadd3448a199!}

{!LANG-0d91e6decf86191afe63433c9bf1a4a2!}

{!LANG-86089c7bd5a44c3a28ebd02bae2710f5!}

{!LANG-137793dff2ce1a1898a8564ca9d01489!}{!LANG-fe49a6ef39bf5ff972666f84168e9b43!}
{!LANG-4389e8858077af0ac74fd997485539f6!}
{!LANG-ed2c9d673248a7a02207c2ad9a92a3f8!}{!LANG-d51f98fd761ac30e2b384d08500febfb!}
{!LANG-c85a80906f5834cb33db261b4c8b7676!}{!LANG-b1318e2be14107e23bdb86799424565b!}
{!LANG-9542d9f839fc19ee50e40a0fb335796d!}{!LANG-658020496d4847bdee7623e75cf98b9b!}
{!LANG-e46e65f22f28a956af11c2aafce842ad!}{!LANG-8e1a2434a2424d5d3136b5051f477bc2!}
{!LANG-b16a4dd338992df9aaf4742eb798c765!}{!LANG-2b79e95f3ed05e4eb880ecfdd3759146!}
{!LANG-a85018bbd462f508fbd5d577c576c188!}{!LANG-90d451772c991073b93cd8f44fc507f1!}
{!LANG-8a841fe35fb74aff2690eb3b76a8a67a!}{!LANG-59c230b517e5a1fa5ea681fd21d005a6!}

{!LANG-96726b091204fd2e162577e77d532790!}

{!LANG-a7a1221ed673cac68a1015fb03c4ea7a!}
{!LANG-e5a11b5640c132e6e8ddaa4814991fc5!}
{!LANG-79884b40ca237498e31af525ffdf5803!}
{!LANG-4263229ebdc5815fd48045fac19f9e89!}

{!LANG-6ff46a59e41e51e85c08b037f1e8dd58!}{!LANG-03a074a3cdca92eb28532c1b0f05ed2b!}
{!LANG-359eef792079c5da0d5ab4c0c970bdf6!}
{!LANG-39dc4e7e500d1273dc328c5c40d680a2!}{!LANG-dd17c7cf91f4b86a35a6d63e737e7379!}
{!LANG-4a1e1229a47a451c838ce8bc132a8b38!}{!LANG-619fccb62b6e6bfd84255ba089bedc42!}
{!LANG-204c23e1f23fe974ac0d523302cd8712!}{!LANG-2ee5304ebcbca0f74056635e6e09031b!}
{!LANG-5082dd1947b934b4db407e726692ab75!}{!LANG-36376e40b050214f448afd69c9b69db1!}
{!LANG-b53ba3be0619f86762f69fa435801ed1!}{!LANG-feb5b021345f7b08a7f9a3961e672dc7!}
{!LANG-a019877bb314c9828326348bdf550e07!}{!LANG-99baa0b86489e6f530cf81288bd6bab1!}
{!LANG-c252e86d9b33bbe9407d107aadcbcfd3!}{!LANG-dcceb83824b7c300ae882854f89c6745!}

{!LANG-f896c7f1f6a1fb4b11697d0a392e9260!}

{!LANG-4882b11ae4859770f72d37143d208a6e!}
{!LANG-cb86362e43cabf94711c91b48bc1de9c!}

{!LANG-de9976293570132eac511bea404284fb!}{!LANG-18b826416e64046e3d46bd57344368af!}
{!LANG-986c9e31b6e4298e63983d3c0e632e36!}
{!LANG-6443dcf8f8e3810adffba547b3cc6f3b!}{!LANG-812acd1dcaf624958a4f92912602469e!}
{!LANG-8935348f12fe81bfd6dd85c838881832!}{!LANG-165b2655cdec0bb35fd8d02afb13c718!}
{!LANG-cf81f08b5418fd1d7dcfa0d9778583e2!}{!LANG-f16524d50e678c761d47310e2045dd8b!}
{!LANG-5e5115fdb352daae742029baaf3020bd!}{!LANG-8bc2221e682aa4cd4c17a46da536eb0d!}

{!LANG-285b6ce2c8eb317dccb5ae8ae9f1186e!}

{!LANG-1673d011fd1920cc7640f4a79af94258!}
{!LANG-b85fd323aab2e5e0f0b8d8e3909d6c49!}

{!LANG-245127757a5000e9fd98e893f056f634!}{!LANG-914e03945b1302486913fa1afb3c12eb!}
{!LANG-044eb093587890aa44661667aa4ad1d3!}{!LANG-48d47fc0bbd3f781bf3e4024a720cf3d!}
{!LANG-f200ae86cdc95f0c01b36e39c52a1414!}{!LANG-978e2d05748ded4f211036f8c0141160!}
{!LANG-eeaac688aade3b4800c1dda264d2c421!}
{!LANG-8d76d215595a404e3607c92cd6821cc0!}
{!LANG-e41d900d5ec928a1ad5b8c44ac2416be!}
{!LANG-64872c58ebaf5ad61daa85b69dc72fd8!}{!LANG-e61add5407a4bf37221f6715dd341993!}
{!LANG-0a6e44a0a7da34290730e8658eaeda56!}{!LANG-1c05b15d64766592d08c20aa95b22e4b!}
{!LANG-b10b22d32f458580abdbaa4fd5a0d0c4!}{!LANG-3880743f7fa2677e9a7c4543ff332541!}
{!LANG-0a118edf66835b536050a1fac2ebc829!}{!LANG-526ae3810ceba8e64acbc1e9d12e91c3!}

{!LANG-b1e580f0b102c4274e2ec0e1022600b5!}

{!LANG-a88a99770dbb29213c5c4b8f34b5503e!}

{!LANG-f3bde8369e02cbf40eb66556992e72bb!}{!LANG-ef7584d3919a3e060d2b4270e00583d9!}
{!LANG-2d0b4df45b8f9abac7e231cca712a42c!}
{!LANG-63e5d24ddae835dcc9003e995069e150!}{!LANG-a80bc85a179962e87f72c62a78755ba9!}
{!LANG-69a5eac4c26cda39134ccb55500500e9!}{!LANG-207dec258e49a457e79320e88798d8b5!}
{!LANG-20fefefec66ec2ed15c4d006bd750c4a!}{!LANG-015c2e12e4bed477c1df37fe613e6b7b!}
{!LANG-190bbb9637e1f2b42465c1ffac982947!}{!LANG-e7dd991f994f0113ea093b59352d7a16!}

{!LANG-a816559d02c4978871cd121a6df92cc6!}

{!LANG-f707282a8101a704bd259c1260319796!}
{!LANG-d092cde8aefd47b7272b37583d6d1309!}
{!LANG-46421acb3f34d8f89d226c67d8e44cb1!}
{!LANG-5d8de9e103cfdaac9e8495ce7b2bda7b!}

{!LANG-99cc9695fff7b5d98bf2d9c2183d1fef!}{!LANG-6073aebf7741acb25df818c802f24620!}
{!LANG-313bed3bfa167e96bbacdf296ff376ef!}{!LANG-85131dad7e94dffaf32b3034371de0bd!}
{!LANG-d49e9b47d586920bebd9749ce15a981b!}
{!LANG-23d41dead392094d1bc546ded12daa5c!}
{!LANG-be900578c15248ff05da51627e43c881!}
{!LANG-5bd56beaca520226501e2d7f59a4fdae!}
{!LANG-52422210ea1b14417d44d5873f0ef9ba!}
{!LANG-4e4e438b8d98c0d185278573b7476037!}
{!LANG-c1ccedc87b5462fb4ca08644a92ebfe0!}{!LANG-30a159b7f7a502ff8794cedc0e2be361!}
{!LANG-80a462e4c532958564ca74efb8d66e7a!}{!LANG-8c7b1c592316702229523983e63b023a!}
{!LANG-4af531cbd681f42ae7bcebc76b27dfde!}{!LANG-6c0f4bf166680987ac99be44dba20b94!}

{!LANG-d345dca6dc54102dcf9333a8d67b09f5!}

{!LANG-e520a9452f4b23b4cc63c807a1e5dc9f!}

{!LANG-7c8b611ee4f345608d66392884c7998e!}

{!LANG-321fa3ca967b576c37ad6adc4e8f359f!}
{!LANG-62fc9762f5ab49e316644a68294c160e!}

{!LANG-01adc5c0722e4d4cbc424dd2cfa0ebd0!}

{!LANG-7f237a4dc868556912d86285f2e95513!}

{!LANG-7d1d02deea0e894222b7f90e406d2b8b!}
{!LANG-dc492ec3fe5859b7e53f9e1594f45115!}
{!LANG-bb47ccd7baddc877946dd701b187e9f1!}
{!LANG-2f6613d2a641fd6d34d08ea6ab9272fb!}

{!LANG-0fa9a6989488d4f33440e1dd7145500a!}

{!LANG-1e4a650e7eb197348fad81270a539f24!}{!LANG-9ac9b548213d33fd70769aa9414d76da!}
{!LANG-b183529e9eb28a57aea88dba8a9b8927!}
... NOS
{!LANG-77634a48d3fad55ac11d0ca06ea0b84e!}
... marginal zone
{!LANG-bb5b425e73168f0cb5203fb4d924e0eb!}
{!LANG-e9548bf2292fac155872d6ac4f7f70b1!}
{!LANG-7442ccd67a66d867c65d4f83c3a57d11!}
{!LANG-7a3984456e77046cf4ba1fecc01e8a33!}
{!LANG-ce972f20d3be6d9bd9f45515c9d6b58a!}
{!LANG-9bccfa2a813cfbaf9eb8e650cefb79d3!}
{!LANG-c597eab63723374447f9c20475ec8e17!}{!LANG-5b6ce4292fee8fd53d1d50650083baa9!}
{!LANG-e514001bd4077dd4315a2a798f6a81a7!}{!LANG-e057c9b15d7baf3fcc94aa00c9d396ea!}

{!LANG-f458a5c93899fde70ef9265af2eff2d8!}

{!LANG-665e55c1a92174354c74a0e1ecdf9b76!}

{!LANG-8d22b40df39a25c7ebe6bad921e95ce0!}{!LANG-7afc87592c155b47d1fb9eedc498c387!}
{!LANG-bd5bf7a6566ffe9034276624fb4a6e11!}
{!LANG-a5f8373e2882b2071f153f16a5de95ec!}{!LANG-3ad6f4fdb4c91851646398c96ee92fae!}
{!LANG-ac623a57e6f51a2c53c51b2e1960d698!}{!LANG-6d9afc3f6589e77a248529da6c2abba4!}
{!LANG-bdc760c0ac05d459ff7afa4b0342b21e!}
{!LANG-7fca66dd99c3d06602dc1d0a17aa15da!}
{!LANG-6ca5d4149228886e7727aa9b3dc0b975!}
{!LANG-f4c9a0144c16dc41645f9694096cf15c!}
{!LANG-a6d2b488e2d5a8cf881646999aa4296e!}
{!LANG-dcbfcddb8ebcb21ada5deca14c000125!}{!LANG-3239391e1bbfab8321f689c4d43c54a0!}
{!LANG-fbd697903f6fe6eda8394c1e2c4a6d26!}
{!LANG-cbd4be408a6670e08b944c9a2b695604!}
{!LANG-61e9acea416ba114c1618b875bde774d!}{!LANG-c3080e27ae450e26c06afec8aa840f25!}
{!LANG-8c90ef4f5d81f40d20e024b7bab44a09!}

{!LANG-a57044a6c8b245c0268c0f18e0a62a9f!}

{!LANG-665e55c1a92174354c74a0e1ecdf9b76!}

{!LANG-4c2077080e40019f51e0e914d4449405!}{!LANG-2e08c37b78f0e47888f3d32f9587f9e9!}
{!LANG-8afb97e4cb9c56d945b574bcc7351be7!}
{!LANG-0c63632d1448403561f59616853fc7e6!}
{!LANG-04b191e0ef4b62d5896bf57acad228dd!}
{!LANG-5baf1c30d878aa3cd3885d25c04919e9!}{!LANG-ad3e711b0d5963a0c52e1102832e5c74!}
{!LANG-10a8f0d272a7b1e30957581417bf52fd!}{!LANG-1ed624386b171eccbbea00fbbf17d0b8!}
{!LANG-3af50fe711f13c7e1c51f7ca0ec920e6!}{!LANG-4c2654c44b713343b9f410cc1445841f!}
{!LANG-79d414e99b4bc77f1a3d47577e660da9!}
{!LANG-db16651a341ba40e304967f4feefe8bc!}
{!LANG-8f599deb13c19c0398d29d716df4778a!}
{!LANG-562101473640aa3184b0dcc7a841879f!}
{!LANG-abf27e7cfc9b00af367607b70ac62624!}{!LANG-628c99cb42cc0e6bec6c3cfd1fdc12fb!}

{!LANG-b02757c02c44a44635c9b72bafd8e00e!}

{!LANG-8b1986b5d1cf3209a339b3357a9e1f0e!}

{!LANG-a6267e5102685b302764a5390557c83b!}{!LANG-fb04cbdfba20f445fa2f019f45359161!}
{!LANG-19dceb01e7b89a0498b35dd4b91086b2!}{!LANG-eba98165d485205cb8a03d5216eb5103!}
{!LANG-326ef2908b2c011b9e46155c3c4890b3!}{!LANG-ffaa5dcc0c27a2ac929ff0e90d370f47!}
{!LANG-738d8b4c79fbfe68ef251d4371170793!}{!LANG-c0b190e619b14ff997967b16a500e5d5!}
{!LANG-07ff301ea5ff8078c69863e8ecf939bb!}{!LANG-398cb30ce5ba5a04d355ed085162316c!}
{!LANG-2120938f106eb422fdb6dd410e403719!}{!LANG-de244440e5340c5242ca0f5c143b8f28!}
Anal department:
... the edges
... skin
{!LANG-d53963d1574293c5cecad3403865f1fb!}
{!LANG-da06b5952a3a792a1b309d74c4ff06c5!}{!LANG-dd2183722a836b4deab7f49a5e1c207a!}
{!LANG-3a576118e4454bce55fa7b02226ebf9b!}{!LANG-af376bb0395df4a854bc45ad00320800!}
{!LANG-e17ab3706a153817454a1e36eb322b7e!}{!LANG-04de5378ff29e7c0b913391cda6abe92!}
{!LANG-b31b819374be7383aa47c731db923b30!}{!LANG-d7fe525eb839169ccd5cef5af71b4bb0!}

{!LANG-ddbf5d8b4d3f73593ce2b86f7e4554cc!}

{!LANG-1e02a989bc7d29f5cb0eb963f681731a!}
{!LANG-64cee8b5562663ea162069202144b721!}

{!LANG-cf2bf018fcb661e888412b7d460fd076!}{!LANG-c530234b532630f1f35e2a8b0e1e9f09!}
{!LANG-f6eaa369d6f6b8faec82e9a11c36ddf3!}
{!LANG-3e8e9503767501e28b8164d7327defb7!}{!LANG-31683bdce8c0ed6ef9fc485e2ac481df!}
{!LANG-1aebbe04d01f83b8a4419f9b7a412e93!}{!LANG-32e798547ada886ea28c21d9e32f8484!}
{!LANG-de7e452c5545683d81a4656f2866f6da!}{!LANG-8cdfea3c2f43577b0001dbd5506250f0!}
{!LANG-7fb06ae832a06b5b55730c6cc2a65aa3!}{!LANG-c3ea2b9230b74462f65766337ed4fe10!}
{!LANG-53353267fc227271a1ca24a168e5ba7d!} Torso skin.
Anal department:
... the edges
... skin
{!LANG-6951ea981725e738bc82680630aaca07!}
{!LANG-c53840e22197a0ee3d90cf7a8748e2e2!}
{!LANG-270a2ae32d84903aaf1252d9c3d5d521!}
{!LANG-c7adf4f0d2cc295ddee1145775046364!}
{!LANG-6bf4310df9024dc8c23486333284bfcd!}{!LANG-d602ab6056a222124fa6ab897a040f83!}
{!LANG-007c637512aa24a702cad4699a9608d1!}{!LANG-13463734aa29f67e20714b1fcd6fab03!}
{!LANG-37f24301fb08eb9e73b20863e124de20!}{!LANG-5889a2a76ff9af60a9d71e0e6a900ab0!}
{!LANG-beceb41ffa55e1648c372ef3f922e197!}

{!LANG-19411fb1877a7b46ab5b82b927ef11bd!}

{!LANG-7aa0705db73d858827485f4bd372c83a!}
{!LANG-769815b000e54e4db0e7d0121ee418a3!}

{!LANG-3979668bf2b4069cde33250642f8139f!}{!LANG-6e37ef542ee7dab4603b7611ea8d75e1!}
{!LANG-d46f87fc007f40661acef00dfc35de07!}{!LANG-954790c80c5290a5a1e2bf4b51009764!}
{!LANG-2da0fddcdd9c5ac988e74335d1b99291!}{!LANG-76caf39d1547f7f8db09f97c7338f6e3!}
{!LANG-0ed94af9e046a9e726fdff6f10578fea!}{!LANG-e47714d78e9edfc3164cd7b0479927ef!}

{!LANG-50b1d7ccb461c11d34c071fe5f5ffde2!}

{!LANG-62d2f560fa094bb72e96f452faec4dc1!}
{!LANG-8f1ac777dc0b717cac4580c442d0f812!}
{!LANG-ac5696166e7c04a1b8c537008f5ef93e!}
{!LANG-80433d994a27143354d86e733d86a666!}

{!LANG-33f8815a678be42216f999d1b616800b!}{!LANG-3233d26cfc8898cc22caa592d3ab4912!}
{!LANG-fc1889f3f3e5cead8d9639422d3cea09!} Outer part
{!LANG-6b162f81dcad9f739f9e075883f52d0a!}{!LANG-51e05ab593da9022f3698a806ac41c4d!}
{!LANG-a2e9585a36ce746e3ee13ca215f7ebac!}{!LANG-72179a1554bc821aa694945a5d99e085!}

{!LANG-ed6bacecba866d9a99f15c2d2127ebc5!}

{!LANG-33b666e3f7cd03d166b5fe592b34a808!}

{!LANG-4c4ed07cddceabc8a20c7e53141b6ce0!}{!LANG-f21c495bf229e7cf7ee8b48b6dbee2c2!}
{!LANG-61ddf652384884be862f8a9fe4bfdd4c!}{!LANG-3a3589c8a942653f3a854b04e5400897!}
{!LANG-7092720d65e699962082edecbbddd1ba!}
{!LANG-9c49c9b8ca451b67e4960b1681333b01!}{!LANG-e0cf1dabef26bede00f191a137c62f75!}
{!LANG-05c94ff97d84d0951c732a1c1b5c70b7!}
{!LANG-b404eaf1b495e44d62918f9e30ff24c6!}{!LANG-93c7a918910a94900a1e6ddf33903859!}
{!LANG-6786ed524c11ca98aa9e8ffd89e0d4fe!}{!LANG-2a2d81a98a6f9b3390e8d95402298f75!}
{!LANG-e55828b29308d68000784b0af9f3315d!}{!LANG-bfe04584d34305f6797346e7bb286e9d!}
{!LANG-aba308b520ae57b4b6f99f71cb093f8c!}{!LANG-35d3587651ac672b23579564268d7f11!}

{!LANG-e4b16df99c0a17c8be16d615732a039e!}

{!LANG-665e55c1a92174354c74a0e1ecdf9b76!}

{!LANG-610012c7a5bc153b29224ddf920e96d7!}{!LANG-59991ff4cad1e8c1505f48eb725f6756!}
{!LANG-70ebb994a06760d186df4932780c775b!}{!LANG-91773e3d5a6b1a5dd61e4cd651460ac7!}
{!LANG-ed94dc46d0f0ee267c2fa55dc3022db7!}{!LANG-512ac3a676a057d0da0fa5604c5b2805!}
{!LANG-61701844453e1780001367d100dbb222!}
{!LANG-8e2f8f49ce7dfa99299d639564b414ce!}{!LANG-a2517e88ffb0858706afd1ff23f798ff!}
{!LANG-06345b1f2968adfb304c48baec3db20b!}
{!LANG-770f558d0a481f40eee10b6f253fa7df!}
{!LANG-58203b41839466ee2518cdaf1ec3f0bd!}
{!LANG-3e6883213bdaf0daa76726235b969558!}{!LANG-ed61b7d3ea680adda503109c09a2736e!}
{!LANG-e088b56db5f78eb70da7e29cbd0fee88!}{!LANG-10363fc0c3922f40dd14cd9d4dd9bf7f!}

{!LANG-4147f914ba16c95ef50927beff7657e4!}

{!LANG-9886f5f59c110d5be370cdb8da078c54!}

{!LANG-7ea04e472189163a7de74a13f9f948f3!}

{!LANG-10f91ec366cf905a3da0a06cc6eee5cd!}{!LANG-47c65a861f287047ef026e7e3fd0318a!}
{!LANG-bf0bf1e25e1ea3ad119b1ab76ea00aa0!}
{!LANG-1b786f75c43328e4b079d64c90f7463d!}
{!LANG-17b513e54e66bea2767f7cbdf9f8f9cd!}{!LANG-6f74a5512e2caa71dbc1f0563d3fd5db!}
{!LANG-c08e2c1b5ea2eb2d834d87720c4172a8!}{!LANG-bd0a7f4f6b34a597ccdece9b303237db!}
{!LANG-12435ecae179191dec6d9a11706eff36!}{!LANG-66228ce3c03215fd65896ab2c77fc9c2!}
{!LANG-fed0d55414ee4f8c8439c4a456dcf47c!}
{!LANG-4741aa96a67c4826fc186704cf1d68b2!}
{!LANG-8e93be525e410b98a89d90db0a6c26c2!}
{!LANG-5c3b3b265fc89a1b8d3fe84827b7ad5e!}{!LANG-e7bf1b22e12c6bc408c03799540fed8c!}
{!LANG-56eae3d8a8a1ce305f63293a6ae0aa4b!}
{!LANG-338953e60a65640979abdbf5cbac541a!}
{!LANG-801e8fe7984bf0ee5f31a4b8dfe75637!}
{!LANG-cc2ac6b6271e531b174d29bfdecee404!}
{!LANG-bea1e2e9a4505d509b1160b4185fc103!}
{!LANG-76d581841b678cc72478a721958a501f!}{!LANG-e160350afab1fd157d1058a12e9391ba!}
{!LANG-57969cd66a9a3009eeef37de9d403c64!}
{!LANG-14de4a74c6371a6541bc1e8c897ebddf!}
{!LANG-d1de832bbbbb82df2a851368d74a7220!}
{!LANG-934ae2851c77cef5a5b0c2e16cbe376a!}
{!LANG-f435d9798c667e95b53b0033bfb90e90!}
{!LANG-e9b6ff5e7d1ebeb3ced86496e274f45c!}
{!LANG-c698210a7aa443aef855577ec6cb8c03!}
{!LANG-08b30dc49f671a4505457954a824b859!}{!LANG-adc4fb31bdcf10dcf7af89a7693801fd!}
{!LANG-65a949f8ac0952794a2e8efabf62ce8b!}{!LANG-654caf0a85ad69231a718d723ca1f2a4!}
{!LANG-46f96dbf433b98053effbe018cbb9300!}{!LANG-4c9a304c7270cedcd8bca55a81d294a7!}

{!LANG-bfb7700d60e42be7e6dcc02f4bcdd70f!}

{!LANG-391270b0c9df9374e2ae0252cb751d0e!}
{!LANG-74411ae01a9320d3ab181842f4e32419!}

{!LANG-a516793306c35bbac884743cab8a3734!}{!LANG-6e88612e5c8ee1e69d06c24e0cd846ee!}
{!LANG-a56362d1a07f9dde5ac0d47299b63c85!}{!LANG-045d504dc4ee18dd2b2168dcdfeb8e9e!}
{!LANG-6cacde415ba0861a706b16e359447e7f!}
{!LANG-3737aeacabc82823548da19857f95b01!}
{!LANG-c96cfec9a366ca930b0ce2974e9ad1b0!}
{!LANG-14a3c792f8e6607f4c2aeba35756e2bb!}{!LANG-e50288158b7bb1e8df9aa89d5825aeb6!}

{!LANG-5992e4c9b58a049b0623f02d37da8519!}

{!LANG-eb4f9d227880044d473474a5611682c5!}

{!LANG-16e98053d92c98124936c687eea752e3!}{!LANG-1703bade049c51a9bab861dd620a7d73!}
{!LANG-0d71b324856626dc0b799d1a9bc57f5a!} Vermiform appendix
{!LANG-5724f67764e12ce46e413b8d0d308e26!} Ascending colon
{!LANG-fbbe3bccc71f5f9a75bfc15443c67012!}{!LANG-93d027e836eb510d8e03de352cbb859b!}
{!LANG-11112f47d6e8cdfb8489ac3c760ce9f3!} Descending colon
{!LANG-eb1b4317e0fb9cf0667c692aaf79ece2!}{!LANG-7c65b53f249c900c4108b03af68f2b0c!}
{!LANG-65933dce05facfe7a9ca97ed2d7cf95c!}{!LANG-ac15131d44f049f460850b1134f88f7d!}
{!LANG-40285a75cfad4e7d3bb72329a0baf0a6!}
{!LANG-22ba271bec02c9c3382f0b84b8bb17b2!}{!LANG-3ad6f4fdb4c91851646398c96ee92fae!}
{!LANG-9876a905a490ba07316d02792fcbee6d!}{!LANG-9b6ddb627a79d278321954a352feff9d!}
{!LANG-3c84aa7f08a28ddd71853bd810c0601d!}{!LANG-88ef4c85b37d7bd6b7411aad849e3ddc!}
{!LANG-7fca66dd99c3d06602dc1d0a17aa15da!}
{!LANG-d50610d7729a47e8d515359a7d244bde!}
{!LANG-531a8998dca6f201c04990207e30c502!}
{!LANG-bf105531ef966cd0de92d3b301cf352f!}

{!LANG-aa383abff628cb18efc7f3d870c0bf7a!}

{!LANG-1a647d69a3ea3c360a5c4b5a47e61e01!}{!LANG-5b6ce4292fee8fd53d1d50650083baa9!}
{!LANG-308b3c7074921a15dac91e49490fac00!}{!LANG-76d72ded966146a74485ad0e0233f3e8!}
{!LANG-1bed57df0e78599360cb94cc214cfd08!}{!LANG-3de85034f48ad5eba5169243911689cd!}
{!LANG-03a0f75fbe040ce76b119e7acaef43f4!}{!LANG-4d4d389818e0cf0e6e1cbdfff94da22b!}
{!LANG-b26ec59122ec92e3ba5aa414bd3b79fa!}{!LANG-f0b6df95edbf43fb58061af41c1ee6a7!}
{!LANG-69208048c65d3337b0210bd43926f244!}{!LANG-f753bc7eeb8492d9c1075767e6fce15e!}
{!LANG-6834e6e1b02919437308e68e16777af8!}{!LANG-d5b50b03df0b9eb79315ffdcfcc1087c!}
{!LANG-9264c45d5cc6a070032b8f5a6bfb75ac!}
{!LANG-9ab780bb191783b739dd017e2cf7b647!}{!LANG-94fd997428ff9e10eca3981261c21a69!}
{!LANG-ffc8b744bcd4cc2f7dc4c9f7d7125f7a!}{!LANG-8fa44b23970b9c7884818be823e160e5!}
{!LANG-d57a01cfdaa034c1fe79494a5dbb2e03!}

{!LANG-11c915c24ccec821c4ca781fe2d1c93e!}

{!LANG-fd0eabc78cd8694aaaeeba031eda5666!}{!LANG-d0801f78960b4f14461f288a61441f54!}
{!LANG-e3b441cc3a11130c60a685744109d965!}
{!LANG-06729d8ff6884728bd0c5e353aae5e0a!}
{!LANG-e99de6c9c2e5032f4ae105bdee8e2e81!}
{!LANG-01861446b1f7f8880687ee07882fe184!}
{!LANG-47a4833008333202935c27e5185acc77!}
{!LANG-377a03c6d752c4abfb5f47d36603d7fa!}
{!LANG-db16651a341ba40e304967f4feefe8bc!}
{!LANG-3ebd3a68001659fd01a40f3eeca2bbc5!}
{!LANG-803576fedee79c47a5ac02b40c7b1861!}
{!LANG-233bbaa31c3b84caf5b86775f2b14857!}
{!LANG-8ec9cc645b05a9483d2386c19450057c!}
{!LANG-d551a4adaf4705cfb76f70dc6ec8881d!}
{!LANG-4fc711b8eb4c7af739448d4e32729512!}
{!LANG-405ca7d91cc0531c2a3e87dfe85781c6!}
{!LANG-0d7c09213d83d59df1015cae504b3664!}
{!LANG-2e251b69b5ae8afc67c7c20475a1cab2!}{!LANG-304735cca3fa8eb53827b2d2c14a41e9!}
{!LANG-3ea9722778c02ba7e9bef6454c3aa778!}
{!LANG-db30a293bd5f56268779402c10f62818!}
{!LANG-051be048ac5bdaf6dfc9f6ec816392c1!}{!LANG-ad3e711b0d5963a0c52e1102832e5c74!}
{!LANG-a55689d6a340af0242f8a22cfddd7ae6!}{!LANG-1ed624386b171eccbbea00fbbf17d0b8!}
{!LANG-9758c6324d00df329c01dc3dda1900b9!}{!LANG-c7550dbe4d9b6db6dfaae4d3d1325fe6!}

{!LANG-028b004d10b714b9f50d97c1b7f1a534!}

{!LANG-23bf1484f66a8397f2898fc91a1c0cfa!}

{!LANG-894382ae7e621f672421e12d4c71c562!}{!LANG-b9a5743f5caadf304432707dd46f77ec!}
{!LANG-ac316a101456f999119fcab6eda51195!}{!LANG-ad6833c3ef5672926be710099c24ed51!}
{!LANG-a41bdf78715080868c6a0c19fe8e1f8d!}
{!LANG-c0fd49fd97d7a703f6798a3331ecf844!}{!LANG-ee48aa2a0b4df924ee4091c284f608e1!}
{!LANG-f4bd344de8b5d2866cb851622dd3f40c!}{!LANG-1919e779c77b82f5ac89b432428fa8a2!}
{!LANG-818df4003031150c47228a368a6751c4!}{!LANG-7fa469221e072ef04ff18c5f1e5e32bb!}

{!LANG-a32805ffca4ea0e8adf6296aa652ba2b!}

{!LANG-f3c11e5ecab9e82f080819175d2763be!}
{!LANG-9aeb46c3dd456e4093011286555b91f7!}
{!LANG-fa82d6efa1ab1a80466311e330a5391d!}
{!LANG-5e6849f23b9f3755711e8ff933ceaa96!}
{!LANG-0cbbdff9103309d511c0364c65525f65!}
{!LANG-06f88c500ec4ca6968a7752b7226de31!}

{!LANG-1d8d81189d5f325421bc68f9f046c423!}{!LANG-ee481cf488ea31e1389906d60e517066!}
{!LANG-6e8bc059475ee127102dd89717a06c63!}{!LANG-da17838958486c58f13ba8c425aadb16!}
{!LANG-aee7e2d726aef3f2fb2032a34db921f6!}{!LANG-063aabea327f48be5b937e53815ed141!}
{!LANG-c87ae42f1c2432576115bb45d99d418a!}{!LANG-4cd53e3bbaa0f08e0db426b81c2877c9!}
{!LANG-9cfadc4cfc074a1e2f73dd6a66ce02cf!}{!LANG-cba2be478c8cd66d5b908defdccb37aa!}
{!LANG-1133d2887da6d42216e4eb30a4775838!}
{!LANG-c03759d3397a95f611c60196240c8773!}{!LANG-02e489c253b2da1928e9e64761871071!}
{!LANG-af8150809e36773287c0af5eda4af626!}{!LANG-b91e9f380610c5dc6203ea9f45a6b016!}
{!LANG-21f1e3344db7ec3400a3c2baaf5df171!}
{!LANG-ff886f4888a95fcc9c4973bbfe8d8ca1!} Ribs, sternum and collarbone
{!LANG-6a602463656ebdef634e5282292a35b9!}{!LANG-d6f211195c29d347839feb83dd3dc472!}
{!LANG-7a7e343aeee4bc13b7ed96c9de522501!}{!LANG-438cec1b13dd57fff76932ef4a808bad!}

{!LANG-fd8eb7a6bc938df0ac46de47b20a61bd!}

{!LANG-0d482039239b3bbd24577b89b9a601e2!}

{!LANG-536bfd6ee9d004260083d1c3b1253f3e!}{!LANG-7d3c86b337231da63dc798062e07a356!}
{!LANG-3f0354b6fb5beca8b726c6c4de567461!}{!LANG-2d2151503c113019eba32081553026aa!}
{!LANG-b42b9a39698bc01fc09c31f17186691f!}{!LANG-ce87c2e6a350838c1a8f17f988683bb2!}
{!LANG-89f2324e9401a4ec233a2840eedf2ff6!}{!LANG-25b4dd2b6675153a5acfb30ffd2c0750!}
{!LANG-3bb7faea0086853148dc42a050f9c3b8!}{!LANG-2c085b74ff68e4144132bd075a899f3c!}
{!LANG-c2a7f7ecef347a1f68de8e98fe067741!}{!LANG-0aa2c23326560d1fe4b424d1c1c079e0!}
{!LANG-9c966f5e9e1920ca70b8addd745f8009!}
{!LANG-11bd304283596e16c082f93e07d572e9!}{!LANG-aacfeaa0d6be24060f08328bce587c29!}
{!LANG-83020e394d08e5ac10c15e345a4ef4fc!}{!LANG-8ccb7c6e66879675fd32f16de45de1ac!}
{!LANG-869b5fb6bc10ad30b534847fe6046bc6!}{!LANG-2e31549ea3fcadfd9e7ea89059654e40!}

{!LANG-6f1fa5f3bdf79406e50dbab5d76b526d!}

{!LANG-95c4cb1540a1958b45d56a62ec95a345!}
{!LANG-d6350be769c955148de5d72c7e5035cf!}

{!LANG-dae59db375203de135b0ce6febbaf8f3!}{!LANG-572b4613af25390fa1c6d5b4bbaca998!}
{!LANG-1e69e15745beac87adb38b3bece92f10!}{!LANG-9dda5482d501f02c4158dbc4dc434fb3!}

{!LANG-aacb2eb46572f5362fd30461ddee1798!}

{!LANG-3c5caa7fef73f30a8d6ba0972c0a30dd!}

{!LANG-d24d291a3f3ecf8a57e9889f56fa5ef4!}{!LANG-c7d9f4b8a9d2e7156b9451c7f34fe12a!}
{!LANG-3e183f0c946243fe5aa23c1344acf01a!}{!LANG-a05c9ff3e5f4a2c88c4debfa7e062212!}
{!LANG-79face886511e1a79288ec70f3c2b750!}{!LANG-1ca427e3b5aba120ef30130eaaabdea0!}
{!LANG-bd7b4b1dce7c9b20547b51a7f6aa630a!}{!LANG-289ec03436e00e5e8b16894d95215e8f!}

{!LANG-3aa33f78da964aaf8814bedec9b19281!}

{!LANG-7aaf2a169ee2e01f71aab5a6f025026b!}
{!LANG-b0372266c38e5e0637bbdbedec5ea9ed!}

{!LANG-7398fd396a39bd4ba7f377570e8f0bdb!} Retroperitoneal space
{!LANG-eb09c4b2398eaabb2bec4de3d014c3b8!}{!LANG-4a256c2d2a90e1b06915e0acfcbec7ce!}

{!LANG-ca24eba307b7f9979aeba565c7ae25e4!}

{!LANG-27cb3035cffc3a84600ddec7870d44ce!}
joint capsule
cartilage
fascia
adipose tissue
{!LANG-b99acc2a0ced0f62d0b7eab797f73ce5!}
lymphatic vessel
muscle
{!LANG-462a00a716c036ebe7bf39e6b2de6779!}
{!LANG-d6cf218173ec603202b893e8f21773e6!}
{!LANG-50b1b2cbe81a64149c08d1d2186c9010!}
{!LANG-7f50b44c37f37a0ba9ac69a6970fee97!}
{!LANG-5e6849f23b9f3755711e8ff933ceaa96!}
{!LANG-0cbbdff9103309d511c0364c65525f65!}
{!LANG-c19ef0cfbf839580c3f8e3751099b8ae!}
{!LANG-88b6974a50984c098abb165e2e25ca83!}
{!LANG-059a4bf1100c9b31aaefdf5aad4d2e93!}
{!LANG-3fd6d82270ff88ccd54e804af0cfeeb8!}
{!LANG-37bf0890fb039ec3f9056c8f0a1d7e87!}
{!LANG-9dd2a2f39e0da6ea5a672ab4654c32e9!}
{!LANG-d2cb6826aa8052b2b7ac088074354823!}
{!LANG-9193a14a6a652fcf0863ad0a2d6b2202!}
{!LANG-3be34c0634dbd26fb5d85a4f730e32ff!}
{!LANG-f9353402dfd5d57ef1d82110392660d4!}

{!LANG-b6b789fefc6f8fe6d459cabb789c526a!}{!LANG-5bc586afe677b65def609602338695c3!}
Connective tissue:
... ear
... century
{!LANG-006acf6ad34812c12484ec4ab8874388!}
{!LANG-36682e80a681ac45ed058436b7e5f494!}{!LANG-f6b6017b183d5a8929f0ab613471430e!}
{!LANG-e22e0a1abeb4648e586612c3910a142f!}{!LANG-1b055bb1d33771a8a0ee6604f4a80986!}
{!LANG-50f3593bb71fe389ed4cbd6ba5cc3794!}{!LANG-fd8450245159f9d37148679c22d26dc8!}
{!LANG-7da9a67a1a9117dd2e6be8b089e57fea!}
{!LANG-5a4388b0cb655432c7d6ed9a1eee2d05!}
{!LANG-b5768822bb309c721bdb98545c4dcffb!}{!LANG-07803fa4e7c37f650a8d35a7215790bc!}
{!LANG-7dc4281d948e2951cd88571edf1c2803!}{!LANG-c70ff46ab7c37c00c6383548725babfb!}
{!LANG-47150b09257fed311c1bcd347063d38f!}
{!LANG-9193a14a6a652fcf0863ad0a2d6b2202!}
{!LANG-3be34c0634dbd26fb5d85a4f730e32ff!}
{!LANG-f6c66379e2c668484347ae7ec11f32a6!}{!LANG-94ac289c6d8ac4713881802314b890b0!}
{!LANG-7e12c24a0858842b3da2d38c28838118!}{!LANG-1ed0bcda584b2947a802e2a86b9201d6!}

{!LANG-1127490541ce037c4514c70b3ab3f44c!}

{!LANG-7d0960649a0d2d7052a5f83fa34ead45!}
{!LANG-9d391c14e7d5d7669c8ff04b6178552c!}
... NOS
{!LANG-41c78942aa9a3274fdbc58159280a6fc!}
{!LANG-864401c051eac60f39018df99656d1f1!}
{!LANG-894430a4dfca3931efc147aa84427b6c!}

{!LANG-a6482c572334440d36adb892ae688aba!}{!LANG-10f069873f105b00d2d73e39d3856e43!}
{!LANG-8a88405f57f495cd60e6bcc359f08bd6!}{!LANG-766cd6ec65db6087a285d290188d7440!}
{!LANG-1deb4aaad57ef38ce50cd267dac7234a!}{!LANG-cd35c470ce30bee159cc772394d69eea!}
{!LANG-45d4489c6b0ce784201c368b239fce44!}{!LANG-9fc9d81cb3d523f0d031de1f2dc23ad6!}
{!LANG-20afda11c928ba3f6c4e68aa15ed6978!}{!LANG-03f3adffdf1e32dcfb87ea593f112ee0!}
{!LANG-61e4d85b92d974fa5d5f481bae7fad18!}{!LANG-ffd8c0da4823ae6c66b920be1476b1b5!}
Anal department:
... the edges
... skin
{!LANG-c9fdfbb196bc5c13d8ae556f5ed9af5d!}
{!LANG-3eb36a6365b649dcda94705064cb9aca!}{!LANG-c50e037758ee576690ce16360c4aca3e!}
{!LANG-a852f1226c9a13a9e439eaf98e5f5d6c!}{!LANG-181bb00310a633dd43c1358217bfb16d!}
{!LANG-face70f7b6974788cf647a3f7b48b6f1!}{!LANG-5f259ab17c857d5dcc437636ffa39cae!}

{!LANG-6b94d74a783238f6a0babf836adb9b4b!}

{!LANG-b736009b20612882eb28b8e2cffe62c0!}
{!LANG-24087de9251d50da009d170e628e14a8!}
... sebaceous glands
... sweat glands
{!LANG-054af18f4c70b1ff5c225f9ce1f26b38!}
{!LANG-146aa9fa7d6e1130bafab5b3a89b936c!}

{!LANG-5f4fb77d9229820466d0d872ae0bd240!}{!LANG-05ce80001f6a4db91145724ac71afe7f!}
{!LANG-9b2ef235ad56c257b7499489a9b07590!}
{!LANG-5636e0a1f5982c4066122cbc5b9e1662!}{!LANG-91268f19af689122ee7b2be3c0adbccd!}
{!LANG-a1e74a51511ff091bd74856ee5efb99e!}{!LANG-32e798547ada886ea28c21d9e32f8484!}
{!LANG-39169483921e3fc86fd95064c47c9f95!}{!LANG-8cdfea3c2f43577b0001dbd5506250f0!}
{!LANG-78042cffb6093208d69d52fd602b6ab9!}{!LANG-c3ea2b9230b74462f65766337ed4fe10!}
{!LANG-df19ac7bfcd0869d41c57903d6823517!}{!LANG-ad36b9bf72f3f7d03fc0b217049b93ca!}
Anal department:
... the edges
... skin
Perianal skin. Breast skin.
{!LANG-6b19bc907fd936d19ca6c7a22295f976!}
{!LANG-09336973fdae609deeb509511ae2eca2!}
{!LANG-f1dc4edfbec9511a9c9bfd7ba8168926!}{!LANG-315356846bb27bf7a8f23cad1d28d228!}
{!LANG-2b0541762dd7f1bd11b846f77fd5ab8c!}{!LANG-7ee16f665a6699b0461b420286469d32!}
{!LANG-9bdcd5123130079498dbdb21af6829bb!}{!LANG-250c2e7377012e6a9d14bd621b46e4bc!}

{!LANG-e90f7b1e6258e14e73ac61fbea334603!}

{!LANG-295170c68b68b6c244a2b1f2c7b626f4!}
{!LANG-2934ede4613a8533478b32c19f36d3f5!}
{!LANG-3ad373f50b7551db362a9ad971cb3527!}
{!LANG-e2a4cf3091a9116adde81c928299d7ae!}
{!LANG-1b5d68a7c1d221f4bc032e02061adb46!}

{!LANG-48692da3e325bb58f8fe670823f8b1f2!}

{!LANG-d1652a8b3aa6debe797fdc28c0ab9ab1!}

{!LANG-85c06242b2b44db5537c5c9a6a34730e!}{!LANG-21472586e08cb78cb3fb2bded7e09b51!}
{!LANG-fcf737ca3231837fde95f33c2980a461!}{!LANG-a60b4a3a10da43c4015024f9c939b432!}
{!LANG-32e2b8c3ed454cdc7c18ddae6e67d0fc!}{!LANG-11fa7664a6008e1db5f9a4e2988267d2!}
{!LANG-1af8be7b3c365ac89b5e2ce7f20b6d37!}{!LANG-d1a154d4062d1224a6b2f32cd955014f!}

{!LANG-404d518b8bf11bc311888291c58f0526!}

{!LANG-3d7788254290c29143890535a602ef28!}{!LANG-0e63a19de93b3355d83a89a0e4f7b7a2!}
{!LANG-bc200bfac258123ab93bab079e851d12!}{!LANG-d7e8f14f8431960b681c9e668fceed8c!}
{!LANG-e5299fc97137ba21cb1f41c43e8f7486!}{!LANG-adeb0d45862d38dd86b8ccf6fa86ebfe!}
{!LANG-8cd3adba8b9809417833323322d1df73!}{!LANG-7b56d328b9b34a480ac82b162431b145!}

{!LANG-63f77499e4fb215caaf6aa33e969264b!}

{!LANG-9332a4d1260be4e2117d08aec4a35516!}

{!LANG-f156bdf2f40ddf4a72ca5a76a2c8e1d6!}

{!LANG-83104692523f320f905e927a22bd6cbe!}{!LANG-ef08a3fefc8788e2007e1ddad1e0d253!}
{!LANG-fad9ce227b57928f454e9169848bd89d!}{!LANG-dd14d2a4100b93dd5ac6b4225726904b!}
{!LANG-9857c1a2ef2f030aa7aa4c25cbf303c7!}{!LANG-0e13f93af56766cbc14e7e4e06a5d90f!}
{!LANG-08de9c1d1c28c55ccbdc0df589c61644!}{!LANG-b97af49c4551a0769d14f2bec68d78c9!}
{!LANG-ed4a2e90e6667e1860feb10275f7fa60!}{!LANG-84c84ba8577aad3ba15427707c5c19ae!}

{!LANG-260fea2d4624258df125f7dff59bbc51!}

{!LANG-84e89180bb7fc62ef3433fb56820d2c5!}

{!LANG-5b1ecc18745e685e16ed79e95a81f693!}{!LANG-5017204ca1dbab15d3ff117946eac9e3!}
{!LANG-548d2c31b051fc2b3fc7806c0e9cde49!}{!LANG-4c61acd05c48b0a2c36f82cbd27ce20e!}
{!LANG-c66b75bc70065ab32a1ee58794fee9d1!}
{!LANG-60dfddb2ef9fbbfe4fd7e6134c659f21!}
{!LANG-d4394b381338a5c4aa25c1fc4bc81de9!}
{!LANG-05e89d3dc5c6659ec1493aa54e46a66d!}
{!LANG-a9cc9b81614ca081f312d9e57a205bef!}
{!LANG-079e1bfeabaf1c9cd6a5d7599ecd82df!}{!LANG-f26959aa3395438f2a69f9399782f46f!}
{!LANG-3b2e6709ac2a0e03c3d34b549dae6f34!}{!LANG-d37810d756096d7444304b028ae4cfc6!}
{!LANG-3c2e7e31378e90d09dc89080ac5c47d4!} Scrotum. Scrotal skin
{!LANG-857bb18b183cc6bc429fc954bdc8389a!}{!LANG-fa75f8775e96a6979ca4f8a38edb24c2!}
{!LANG-3bd44777a176382199ef123160ac7cc5!}{!LANG-13a0e729f8b9fd00c4f276ae7d4bf036!}

{!LANG-688cd30b06163e8279ccd331296e32d3!}

{!LANG-00d638149c0c54e5d68fb63dca4d9cc8!}{!LANG-0a04d5d59d1ab944ffca85ea9be82e5d!}
{!LANG-58436fb7cca51ed8961428638b3ff137!}
{!LANG-5ac93a7c7606a9e541f22f076602af33!}
{!LANG-44a0e85421048cfba357b0db92690eec!}
{!LANG-09c3f807e072926f9887d62098a2312b!}{!LANG-71262cf7ce83912301bab3525627be9a!}
{!LANG-2f780e2047297032026dc1f79eeada4f!}{!LANG-f3ee7606d9efd416f54f064ee23ecc84!}
{!LANG-035cd3a9e6f589d194c68f715e3ad64e!}
{!LANG-7f1c06081b744ca617217b7730e42f95!}{!LANG-7fc1f221bea755967dc624950fa22ef8!}
{!LANG-fcd9dfdb26172910fba75ddf0db268dd!}
{!LANG-4380c16c690e993d30164b282c5c5a2d!}
{!LANG-fd34034f7aeeeebad4414f1f5c5adc82!}
{!LANG-3b20ffe9f7f8419c25c9f445b3c80d9a!}{!LANG-b5c5c87d8f2a70b5e5332daa06b60c32!}
{!LANG-a228aeb7b2a6464b6c8ac5732abcab7c!}
{!LANG-90cb6aaced24a6af8cdfb200e9652688!}{!LANG-8e9db7b3af93eefc77e5d98e8de532b7!}
{!LANG-0feea3fefe7dbd905a6db4c9d554269e!}{!LANG-ea772af680094adcff8e2e53e51b6922!}

{!LANG-b166694ee6d22e9346ab4971824b7139!}

{!LANG-fe86a74dfae3cca1bcae8cafc596d83e!}
{!LANG-1158c851ec71d1ea0b8b4aaf1d6841eb!}
{!LANG-e5105e5aae9fdf7d1790399b323381a3!}

{!LANG-35ab0b20c7db86dfc0263b5a86737612!}{!LANG-0bfe8473f84d1c606fd8705ab64fdf09!}
{!LANG-95bfd6948e90d93a8ea46fc87f1f58be!} Cornea
{!LANG-b23618a53505acdfa9c4dcf215b0a300!}{!LANG-9f4d6f2ab4fffe8af9b56dd5af0f9cfc!}
{!LANG-c64e4ccdf271e86cde8007d9a06c1654!} Choroid
{!LANG-cea355845e1424b18ff70fe229129581!}{!LANG-712b5cafd22c729fbe93367d997f3393!}
{!LANG-7f6b26c632a38f08a1988c4f14bfd460!}{!LANG-880982004ba6ea51537bdaad540b6b1c!}
{!LANG-ed9f1c41b344492ce8063f447e9afc1d!}{!LANG-33b4a31c83d63ba88cf011c7d3bcc54f!}
{!LANG-80d2e1e709d61bc1c2659c82afe806e3!}
{!LANG-6833ff6526316e32afbb385ca125745f!} Eyes, unspecified

{!LANG-1b7ecc85ec2657a556bb64cc6f76eeeb!}

{!LANG-a11d5a1f36eea807b0c34f7d29dd2da5!} Meninges
{!LANG-7488e5426574cde8f21dec851d52e537!}{!LANG-deb7d787b6af201cd04e48cfb1ab23d4!}
{!LANG-7cdb661beadbfdc86025121844fe7530!}{!LANG-6c96e88e035d7caa330d2a9923b5f7ee!}

{!LANG-80a0238e940324dfdafb922bd3d56024!}

{!LANG-1fc53cd2c1f874150a1c6103cc2a39f3!}
{!LANG-66a2e151bf6e0cbcfdbef30be87e7fec!}
{!LANG-d574bf99196e124e4e96bfd79fa632c4!}
{!LANG-2d18297fc77648528327726ecbbfe0f7!}

{!LANG-d0eb65cc3e885280ec5fe2348d6b566e!}{!LANG-61cba230f60763e07dc9f0e92ec70032!}
{!LANG-699768d3071092d5c3b873ad1492f1cf!}
{!LANG-fcd789bf49a0611a77d7281a4b41a26c!}
{!LANG-19633f85104bcd8ae46a88f85ee8df79!}
{!LANG-c1fb2255d5dd92a8f1bffc95a7d96f67!}
{!LANG-18d2a00ed3e7cb3a2b3a15e0d7c8510e!}
{!LANG-dc30f3c5b16fcfea46aff4f3c1428202!}
{!LANG-3485477527ed0a25bcd997c3dce5d196!}
{!LANG-cf2564ffa899720e19195a9436306d1a!}{!LANG-b54f51e64bc73add4a00607d7e7fb91b!}
{!LANG-7911a1939167110e17509733a3ea5cfb!}{!LANG-a936ebc2f2c9ff2e689d93821a9343da!}
{!LANG-72d406d538de11b49cedaee71687763f!}{!LANG-9dde915800906f231d58a5d5d74f4f4f!}
{!LANG-1fc32173cd0f73b223cca55d1af76795!}{!LANG-9be8a02eed2eefd43ee7240910c30510!}
{!LANG-0cc03822265d8c1489e39829538cb85e!}{!LANG-3bf0ed822ddbc237f6e5865aeb072551!}

{!LANG-0b734d8904b5e83eccf6bf47e023cb84!}

{!LANG-791d5b5d62c4f096b43b21c7f2cbc4dc!}

{!LANG-8ef6e4f2a0b9b02afc6cc8894f13e945!}
{!LANG-fe1f98c4a585e088a730c73d2ba6d0bb!}
{!LANG-9bec1cb718d6a93e9afdbc543385fb30!}
{!LANG-c7e3c96215765ae7ebda688fa9a1a420!}

{!LANG-e08870b9886f93ac4fb1bd17b8e19f71!}{!LANG-e85b7fafc4c505ba9c32c4175e55441f!}
{!LANG-302cf5225c0afacffe373e689362f8b6!}{!LANG-a41a903ecb313c8f68bc97972c3b3923!}
{!LANG-fba440c347d9176e621277177f407896!}{!LANG-b78907f3aaae3042ed398490817f20ca!}
{!LANG-b6af5c3d934210e4699e7252710277ea!}{!LANG-95b18d00a06a53469fd33daeca715553!}
{!LANG-f53409ef14fa353daec373bef90dd41f!}{!LANG-b3acc5ec9d564f944454288a9b9b37b3!}
{!LANG-9d91340c074ae9d4b7dd0394316df574!}{!LANG-b08c7eb240a79c768089c6452d13ebf6!}
{!LANG-928a05727061b9c605f60fb12f8360ea!}{!LANG-8497097ff73610e4377a61ede151690a!}
{!LANG-8f3ee6956405645e76b61cdfdc8c2613!}{!LANG-a2ccdd82aabf66887e71c090733b0a40!}
{!LANG-f2e2a741c64db1d7a3998b03785d054e!}{!LANG-d1ef16219650d0c526a48552d7f566b9!}
{!LANG-2d8551eb043f9b0d47e44abe8a71490b!}{!LANG-0cb7554e05544f94b13caa8377063219!}

{!LANG-3f7b2d1f0b303131882939a92dc4aaa2!}

{!LANG-8d8e74af548ce643a5988524473aeff3!}{!LANG-402b57271e9ad44904ed93cbf113972f!}
{!LANG-80085de45593e96f33db4b42b0ef5de8!}
{!LANG-b5c6e749f4e91298129886947bf1e34d!}
{!LANG-0e7f2d99dae1960f0ebaf7233bf883dc!}{!LANG-84a32e18d63dcd1d57f7ab7f34a28f43!}
{!LANG-17d6a9db921a56d1233aa24ca5427f6e!}{!LANG-f7ee881487c7756bf2ccd39c30ab649a!}

{!LANG-f0193b74894398764f3c92ef7719884b!}

{!LANG-844e93346db9d8326df667171f95be1c!}

{!LANG-7f46ec0c90e1d8a42774bde2324a963e!}

{!LANG-8e8b9327704d564b50a681aee9275f7d!}{!LANG-9ac9b548213d33fd70769aa9414d76da!}
Cherpalonadal laryngeal fold:
... NOS
{!LANG-77634a48d3fad55ac11d0ca06ea0b84e!}
... marginal zone
{!LANG-06065bde44a5795cd530a8832af6cd81!}
{!LANG-55eb57e1c8af18de4f47fc1143317b32!}
{!LANG-7442ccd67a66d867c65d4f83c3a57d11!}
{!LANG-f5c92883715e664475833652f8d74854!}
{!LANG-ab717b4e6bf771fb1a112ffd594241a8!}
{!LANG-ee3db522cf6462273e9dc70c12291ac2!}
{!LANG-51f00d601a7d5ab8f2c07eba6ba35e02!}{!LANG-76d72ded966146a74485ad0e0233f3e8!}
{!LANG-e2d69857366c3bf11f99a51ef4b06486!}{!LANG-914ed899ace0edbb906f5bcd03b2bb3a!}
{!LANG-a1c9696c5e472d8588da9d0a96ac9780!}{!LANG-0870bcd6c5189c507efcc11c6f3fb202!}
{!LANG-2fc92f202d54ca7b1aee29153b772db3!}{!LANG-24cc9632d3fbb0aeff803426eb1ff650!}
{!LANG-69ac93c20507e9ed43f069f9ed4e637d!}{!LANG-529ec36777c15ffde3341a3430702acf!}
{!LANG-b4a853adac79123180e3d4525ebc565e!}{!LANG-5d8e319dde7fc4c4d869cecef3602609!}
{!LANG-cbd723124edf53cc081e30c1043f98b7!}{!LANG-f49ee24d3e6ed09fe2d88649784bf718!}
{!LANG-e602ec71a899845a3936d68d51df9c1d!}
{!LANG-e979ff6a09e49a644bc1a135ae3d5f0f!}
{!LANG-8a9c4d8b7a7550344c85a5cb3709e524!}
{!LANG-db26edfa511b0cdaa756e407546637be!}
{!LANG-7fca66dd99c3d06602dc1d0a17aa15da!}
{!LANG-6e1acbc703cae9b2b7e0fc86d124e666!}
{!LANG-8a96c96b0a50a7975b55eee4e3373966!}
{!LANG-bab4a9e4fbc2053cf05d8c77612bac52!}
{!LANG-f83645f4fddcbbb3aa341816d9dfd8a5!}{!LANG-de4ef3e48bf8779b5700d989960120b2!}

{!LANG-6772961253c708e10ec3bfeee101fc69!}

{!LANG-3247bdc286b260f439c4217f700e5cdd!}

{!LANG-9b10183c6dbcb62b3da6f6d3054aa999!}

{!LANG-c3e9990a0777327e3a79c63d82c7c010!}{!LANG-d0ec8dc11b820cdf42313b9f9d20b153!}
{!LANG-71d1dbd37e61606ce6f77bf46b430818!}
{!LANG-b7d98b3cd11beaef741ebd3f069aefa2!}
{!LANG-b588d7fa49c0cb18da39509e672575c3!}
{!LANG-8a9607bbe3bb02247f6add83335d8d9b!}
{!LANG-c504c359ee8550c694dc29553da22910!}{!LANG-48b848d8c121b6181a7378d5bbfa4c7e!}
{!LANG-fe92522c8c5fdf8fbcfe2902bee59c7c!} Pleura
{!LANG-0a60e11b6ad29fe70ace1c8f8cfec919!}{!LANG-ee48aa2a0b4df924ee4091c284f608e1!}
{!LANG-b1918da05f681d0f0626844077d5fc9c!}{!LANG-b9a5743f5caadf304432707dd46f77ec!}
{!LANG-f82a1d37570ecd4c5a6b561a33b5cb3c!}{!LANG-ff961462c572fe2b186c8be601a584f1!}
{!LANG-28dea54a26c380a0316a921da1b5dc1c!}
{!LANG-db16651a341ba40e304967f4feefe8bc!}
{!LANG-cacaa5f9d2a47d659541931d0bd5504d!}
{!LANG-8a96c96b0a50a7975b55eee4e3373966!}
{!LANG-4bba083be4df4de8f7c8d5824c1abfb8!}{!LANG-5bce94a692c936c6d391b6e5e3c037ca!}

{!LANG-082b9e6f5bcc95f20c812c10f6d5013b!}

{!LANG-90c8823e5ac832235a3d1f6cc6ce68b1!}{!LANG-909605c70b7738e625c6ff9ab4ad8455!}
{!LANG-9cfd4a33caab91c6b42f4cd8ba464247!}{!LANG-160ba16d6a364287d2dce0fc3946dd39!}
{!LANG-9115cbd0fe38d489b27ca3748f20873e!}{!LANG-96ab0c2cc994f613d9a0873430d4cddb!}
{!LANG-907b4aaafafdeb5394a7180334a4365d!}
{!LANG-7dc228b5d7dc2f8ae294b8e83032108c!}
{!LANG-e1777434cadaed56859a9b09516d66a8!}
{!LANG-fc29ba76044adb097ae9df0ab0d90335!}
{!LANG-381945a43cfdba9b373d28d9a58042ce!}{!LANG-cb1e06a54afd53ee4dfaaf6c56f937ac!}
{!LANG-ca20fd2da692f557c247a40bfc330037!}{!LANG-d9c03887b2e67668e2beac065418dc97!}

{!LANG-eaf55fe969e05d1f6fd4c2babd02b66f!}

{!LANG-366c258a4d51344938f3f539554dc94b!}{!LANG-bfe04584d34305f6797346e7bb286e9d!}
{!LANG-6e7b778b2120d094cc0727a1a4cb5dd3!}{!LANG-f26959aa3395438f2a69f9399782f46f!}
{!LANG-e2ce51a3dfc6f44fea3eadf25f408685!}{!LANG-049cd163b8895b3462076fb2827b6363!}
{!LANG-70803e385095ed200fc829795a579a8e!}{!LANG-d0ca132ceb6fe2b56e11a90c9d56a786!}

{!LANG-38f43c0a5fc27022b2e92df0d165e562!}

{!LANG-3395156eec5f37fa823df5cea6e7a794!}{!LANG-0a04d5d59d1ab944ffca85ea9be82e5d!}
{!LANG-fc100fe0344966f31ecb3b5bb8ab78da!}
{!LANG-facf71952058247d509d0a64df2282f0!}{!LANG-71262cf7ce83912301bab3525627be9a!}
{!LANG-196f89224c78c8ccd94923e55e0fe508!}{!LANG-dd227b2f21e6ff81c9ba0e1b15b9af6c!}
{!LANG-1677b2cc8be069d8835dad35ce31cb7b!}{!LANG-6ef845fcf9b2982d1b0cffaf7c981542!}
{!LANG-41c5e897b8e19f1dfe6b3aa9aa8e41d3!}{!LANG-59991ff4cad1e8c1505f48eb725f6756!}
{!LANG-2cff95a88f622f00f60d45bc73863b00!}{!LANG-449281d935568981a245022a2967ec1c!}
{!LANG-1a55b931c64760f74027e89898701045!}{!LANG-817ffa6b8cfddfb95d41654e3f277d8a!}

{!LANG-2be1d8f572cb2764243cb0ce906e5abe!}

{!LANG-fbf8a83370637b08b0871b3af0a525ac!} Meninges
{!LANG-5857314f4a49841e048a9822ded94d93!} Spinal cord membranes
{!LANG-de51412373b35fe2249f52942620aa8b!}{!LANG-40bad11055fea6e4632eab86d0f2381c!}

{!LANG-28aa2ad5e45deb31c0fb9196360a2645!}

{!LANG-02edac81e130d9ba002ff133f59e6561!}

{!LANG-8899307af4dfbd0f3326c96cd87bf06d!}{!LANG-8ffbfd4de24597549609385f9b5e8233!}
{!LANG-310d34fce967bfd131b2726382fa3706!}
{!LANG-fcd789bf49a0611a77d7281a4b41a26c!}
{!LANG-19633f85104bcd8ae46a88f85ee8df79!}
{!LANG-c1fb2255d5dd92a8f1bffc95a7d96f67!}
{!LANG-18d2a00ed3e7cb3a2b3a15e0d7c8510e!}
{!LANG-7b501ce0951425f878e54c9921bda152!}
{!LANG-35e2113f47195455e6aa0e7bd62ce1f9!}{!LANG-8d451091fe8fac540dece35d662882d7!}
{!LANG-5da70802ace31d01b1257ea44a0d1f34!}{!LANG-b54f51e64bc73add4a00607d7e7fb91b!}
{!LANG-ccc8baa6f77b8fed50e2337e7f9c578d!}{!LANG-b3da3207aef31fdd6c5d6c33a7ef8117!}
{!LANG-c666e6b723603e6e800c3ee58f73fec5!}{!LANG-9dde915800906f231d58a5d5d74f4f4f!}
{!LANG-c877ab724337b43a3215759f809e574d!}{!LANG-9ec2b2cafb0b98a823b9b9ee33474076!}
{!LANG-667c4878a879cfc4c2aed519a7da38b9!}{!LANG-138b5b7b2572678698b3768791ddc562!}

{!LANG-36afd2d97a618c1ca3d3b12cf03a8d8a!}

{!LANG-c379680f8ea0c9d42cb21d43b7005e37!}
{!LANG-890824faf86c33f4150df7d46a193d98!}
{!LANG-998583ce3a5cf198049b4ed9e783907a!}
{!LANG-1b0c78f00bf819c31b80ac62c5c492e7!}

{!LANG-eb2618a7b4adcbbfb7da4ab7822b3fea!}{!LANG-619130bada093ac0a8d4747310c2f927!}
{!LANG-0fb61f82195813b9b0a12268314c5575!}{!LANG-e85b7fafc4c505ba9c32c4175e55441f!}
{!LANG-2b67cb92661bf6dcf52d244174e69823!}{!LANG-a41a903ecb313c8f68bc97972c3b3923!}
{!LANG-9cb7213c292ed5560e80585c2a53ec2d!}{!LANG-b78907f3aaae3042ed398490817f20ca!}
{!LANG-b4f7e7bebf86cc1c3133575f7e7a1a84!}{!LANG-ac14542085c0c2c0f2b86616b780a7ff!}
{!LANG-2d5acba415362397232d5b34785eb758!}{!LANG-b3acc5ec9d564f944454288a9b9b37b3!}
{!LANG-e25569c8de5d024d6c863ed88e5e851f!}{!LANG-b08c7eb240a79c768089c6452d13ebf6!}
{!LANG-f02e9a28d35ae91a1607b91a17bcaf6b!}{!LANG-8497097ff73610e4377a61ede151690a!}
{!LANG-9dcf593b4d1d96ba06e62dcdee52752f!}{!LANG-a2181a71d9ef7fb71d03372fe292ceac!}
{!LANG-afa1058a486e251f47510591e4f01f78!}{!LANG-0cb7554e05544f94b13caa8377063219!}

{!LANG-4d440c4d24fafb67e692af46e81483fc!}

{!LANG-6118cd4f8abdb35c39c327f8624c6e8b!}

{!LANG-41ec24aa0a43f935305a54607c96a129!}

{!LANG-ced5339d093378d6eb55e0d148b1f8fd!}

{!LANG-c32120d067b1a210c7b0ff0268e7fd1d!}{!LANG-388c1f413a4268699525150a9aacb56f!}
{!LANG-0b4b25e2c013bd8a013f20ba6d78b6f5!}{!LANG-18556d4951c0d34916a7bfc14c2cebfe!}
{!LANG-566fd7e78c813f9db88254ac09dc7ef1!}{!LANG-843ec0495dc47e4d25e83374543b79bb!}
{!LANG-2ce2bae45209a5015acc7ae1b63c201a!}{!LANG-3bdc2371a365cac57edfab5dad33bb41!}
{!LANG-ae540705b6f4237bbb7496abb603a217!}{!LANG-f106b0eaf6b2eae055340dd68a50c2a4!}
{!LANG-7de6b9f1a2c4b3b801969f98de16d794!}{!LANG-a10b984cc0dc6975437285c61d04274f!}
{!LANG-808a42a05532a111a35e4afc65d77e31!}{!LANG-0311cdcddca2aa95858bf29f1cd76293!}

{!LANG-a323ad5ebf02520a54421fb04042ef4b!}

{!LANG-1aab51d7f6d69f6be1521ed76444f76a!}

{!LANG-989246a5b035da1ba92ce6f71250615f!}{!LANG-a0e9044e03b76a227d2a7929250138e3!}
{!LANG-a003ece9d57f2a0fa345f85c40847fab!}
{!LANG-35699766777c249f5226b8d0c35adb63!}{!LANG-880f601fefde3a913539af1c247836e8!}
{!LANG-332bd54aa8144a8408474fb34034d221!}
{!LANG-ff21b8d384d3a920e09986fc1090fcc6!}{!LANG-04c25e9de9c163c46fa991c43e33e877!}
{!LANG-9f0c6ac48c0f159879dfee1b9abc6ddb!}{!LANG-ebc15519bf07f90781051ca70f7c092b!}
{!LANG-b2904c2a1264d72f37efd1434156a4f1!}{!LANG-97aea770d86132e1f09b59fb04d988bc!}
{!LANG-9f0fadbe4cc847aaedfba08c96a8455e!}
{!LANG-34cc7e97888a81fb536d646c43501663!}{!LANG-46a69c34058ec8c7af7e59508f6b6d3f!}

{!LANG-cc86624e34086c3793e5de225c6feef8!}

{!LANG-116b96d20149429df4a93f836dd6dba4!}

{!LANG-6e79daf3acfc31d760700092b8669278!}{!LANG-3f4105af1f1141a03e80728befee0579!}
{!LANG-4bb4addfc6cfb12098eab93b4314305e!}
{!LANG-d48af58dfb6b18432f19154fcfe56ad2!}
{!LANG-a464e2df59854cec02a43a16b4d86f12!}
{!LANG-904e50ecfc9fbdfc2c9704782227bc65!}
{!LANG-d17d8f70ea91e3aef70a4868859d7109!}
{!LANG-c50fdfaeb119ff7cb64f8574e8fbf0ca!}
{!LANG-687a9b353db72febd47a60b749fbfde7!}{!LANG-10a6e245ac31d6ddd614256e9a1a3f7c!}
Connective tissue:
... ear
... century
{!LANG-4bb4addfc6cfb12098eab93b4314305e!}
{!LANG-b2e772246d7d7327eb09ade582209c9e!}
{!LANG-a464e2df59854cec02a43a16b4d86f12!}
{!LANG-904e50ecfc9fbdfc2c9704782227bc65!}
{!LANG-1b59f0aef46ce9f655642b2f1d8c12a7!}
{!LANG-e956cbea62d463fcfcd63229b79099bf!}{!LANG-31fbdc20ce18cacd4aebfb44d9c307d6!}
{!LANG-ac67b817f1ee7c81c615984b48b4fd21!}
{!LANG-1a8f757225c1ce64243060aebe780ae6!} Retroperitoneal space
{!LANG-95892ffa8cb6601ac436b7550dfa5257!}{!LANG-4a256c2d2a90e1b06915e0acfcbec7ce!}
{!LANG-1a249ce43503a1b453362155335bee15!}{!LANG-b131773fe737e4efb9190f76e3edc603!}
Anal department:
... the edges
... skin
{!LANG-6951ea981725e738bc82680630aaca07!}
{!LANG-11c035cf293b47e694153a1589f479f2!}
{!LANG-690c88d9aa90214c3296999c1688dc28!}
{!LANG-cbd7bca5784707ed6979cb4de65e2075!}
{!LANG-c894f39ee6fc7ff38348e845a57a5173!}
{!LANG-600b22206773bb5db5f9cf450e02d8b2!}{!LANG-699b11caf0fd0c4bc552bb40c4c6e0ea!}
{!LANG-07fbd4cddbf20ef8e91d5b4889eb68bd!}
{!LANG-18f3144cd1b9efe711ae88158ccc838f!}{!LANG-913dc5d154402bdc7ea09a2625be2d82!}
{!LANG-a608306b8b9f64bfa92b3d8ff886f30b!}
{!LANG-69d3c8a5fd420024b6ed305ac5c6b771!}
{!LANG-a4c8cc96cb08ab2d0b982ce8f964b16b!}{!LANG-58668b74ac782fd18983f3e5a0eafbbf!}

This class contains the following broad groups of neoplasms:

• {!LANG-d4a290b55a1aff0787fed151ebb144cc!}
  • {!LANG-e082edafb8688f121265a01f73170738!}
    • C00-C14 Lips, oral cavity and pharynx
    • {!LANG-5af44ae85063920011494d80f842d9c8!}
    • {!LANG-1292f74ac2fa9e2759d65ca6b6a971f5!}
    • {!LANG-5637f16b7cef6d6fbc13efd5a6d87af8!}
    • {!LANG-07c2678cabd964aabf94212b5358c859!}
    • {!LANG-ae7d018cdfb6edc1b081ba7d60b66460!}
    • {!LANG-74734db8673b136d4abcdcfac851468d!}
    • {!LANG-5878d54b4a5812a62d091e9dcb772705!}
    • {!LANG-a756b6997f91e44af3534037658901a5!}
    • {!LANG-7dcc95b6d8bee10ebed1855508377172!}
    • {!LANG-0a342fb25545917256bbb08317841cd7!}
  • {!LANG-09c376f59d635cb08f8bd4a3a0b41e4c!}
  • {!LANG-b319be822685f39e9dbe79a33b072ca8!}
  • {!LANG-89bd12ab1745d98e68f4d97f7fdef9bb!}
• D00-D09 In situ neoplasms
• D10-D36 Benign neoplasms
• {!LANG-340f4747d367b1a4d4ae948b3c3ef082!}

Notes

1. Malignant neoplasms, primary, inaccurately indicated and unspecified localizations

2. Morphology

   {!LANG-d602a2873e1c7658ec65facee44d51a9!}
   {!LANG-c13aa63cf7a4c6bbea38d6f9da182d92!}

   {!LANG-3ddf28a9c93b1420608540e38b3e313d!}

   {!LANG-03bb7db1b6db046a5f70eb99e7916036!}

   {!LANG-a884a079c7528a2db6ba33a5b2e9c835!}

3. Use of subheadings in class II

   {!LANG-d8ac4343d266b5ff1f2e733a625a88e0!}

4. Malignant neoplasms that go beyond one localization, and the use of a subheading with a fourth character. 8 (a lesion that goes beyond one or more of the specified localizations)

5. Use of the Alphabetical Index when coding neoplasms

   {!LANG-c8bd42bdf57b5675ea9a97df559333c1!}

6. Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)

   {!LANG-ea2e06f97a2d3661a7579d5c1e61882a!}

   {!LANG-5b95ac611169a2bb70b9ca9911d452f1!}

{!LANG-06631a439102d6e96e0761c33a2c87f4!}

{!LANG-c352aac0faea86fa24dbe87dda65b79f!}

{!LANG-825f3f57e6d083baab3924922d2e0487!}

{!LANG-7f237a4dc868556912d86285f2e95513!}

{!LANG-5176d80abcbb5dc11ec5317b4ddb2466!}

• {!LANG-c313fe20437fc1a4f398dc062f172b5f!}
• {!LANG-a85ae8203b3233ca0860ec018f3b2225!}
• {!LANG-021fde4ecba69e595a4c3eabc989c4dd!}
• {!LANG-c2d65405b479ee1126ddf8c0bedeeb7b!}

{!LANG-9886f5f59c110d5be370cdb8da078c54!}

{!LANG-844e93346db9d8326df667171f95be1c!}